

Epilepsies in children, young people and adults: diagnosis and management

**[08] Evidence review: Therapeutic drug
monitoring in women and girls**

NICE guideline <number>

*Evidence reviews underpinning recommendations 4.6.1 –
4.6.10 and a research recommendation in the NICE guideline*

November 2021

Draft for Consultation

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2021]. All rights reserved. Subject to Notice of rights.

Contents

1. Therapeutic drug monitoring in women and girls	5
1.1. Review question.....	5
1.1.1. Introduction.....	5
1.1.2. Summary of the protocol.....	5
1.1.3. Methods and process.....	6
1.1.4. Effectiveness evidence.....	6
1.1.5. Summary of studies included in the effectiveness evidence.....	8
1.1.6. Summary of the effectiveness evidence.....	9
1.1.7. Economic evidence.....	13
1.1.8. Economic model.....	13
1.1.9. Unit costs.....	13
1.1.10. Committee’s discussion and interpretation of the evidence.....	13
1.1.11. Recommendations supported by this evidence review.....	16
References.....	17
Appendices	32
Appendix A Review protocols.....	32
Appendix B Literature search strategies.....	44
Appendix C Effectiveness evidence study selection.....	55
Appendix D Effectiveness evidence.....	56
Appendix E Forest plots.....	64
Appendix F GRADE table.....	68
Appendix G Economic evidence study selection.....	72
Appendix H Economic evidence tables.....	73
Appendix I Health economic model.....	73
Appendix J Excluded studies.....	73
Appendix K Research recommendations – full details.....	79
Appendix L Additional information.....	82

1. Therapeutic drug monitoring in women and girls

1.1. Review question

What is the appropriate serial monitoring of drug levels, including timing, in girls or women who are thinking about conceiving, are pregnant or in the post-partum period?

1.1.1. Introduction

For some anti-seizure medications (ASMs), in particular phenytoin and lamotrigine, plasma concentrations can fall during pregnancy, and so it has been suggested that monitoring may be useful to inform dosing. A change in ASM level during pregnancy has the potential to worsen seizure control. If ASM doses are increased in pregnancy, this may have consequences on foetal drug exposure.

It is not known for which ASMs, if any, monitoring is beneficial in maintaining seizure control or how and when monitoring should be carried out before, during and after pregnancy. It is not known if pregnancy-associated ASM monitoring would be acceptable to women planning a pregnancy, who are pregnant or who are in the post-partum period. This review evaluates whether there should be therapeutic drug monitoring in girls and women prior to conception and through a pregnancy, when and by whom that monitoring should be performed, and how the results should be communicated.

1.1.2. Summary of the protocol

For full details see the review protocol in Appendix A.

Table 1: PICO characteristics of review question

Population	Inclusion: girls and women planning pregnancy, during pregnancy and postpartum up to 6 months. Exclusion: men, non-pregnant women not planning pregnancy.
Intervention	Drug monitoring (measurement of drug concentration in blood or saliva) of the following anti-seizure medications: <ul style="list-style-type: none">• Brivaracetam• Carbamazepine (for focal motor status)• Chlormethiazole (clomethiazole)• Clobazam• Clonazepam (for myoclonic status)• Diazepam• Eslicarbazepine• Ethosuximide• Fosphenytoin• Gabapentin• Lacosamide• Lamotrigine• Levetiracetam• Lorazepam• Midazolam• Oxcarbazepine• Perampanel• Phenobarbital (phenobarbitone)• Phenytoin• Pregabalin

	<ul style="list-style-type: none"> • Primidone • Rufinamide • Steroids (methylprednisolone, prednisolone) • Stiripentol • Sulthiame • Tiagabine • Topiramate • Valproate (sodium valproate/ valproic acid) • Zonisamide <p>Dose according to prescriber discretion and / or local protocols.</p>
Comparison	Usual care (dose adjustments made without measuring drug levels, based on symptoms).
Outcomes	<ul style="list-style-type: none"> • Mortality of mother or baby at study follow-up • Seizure freedom during pregnancy and at 6 months postpartum • Reduction in seizure frequency (50% or greater reduction in seizure frequency) • Time to first seizure in pregnancy up to 6 weeks and time to subsequent seizure up to 1 year • Anti-seizure medication exposure (mean daily) • Quality of life (any validated measures) at study follow-up • Adverse events <ul style="list-style-type: none"> – Anti-seizure medication-related (toxicity) – Pregnancy complications in mother and baby (admission to HDU/ICU for mother, admission to NICU for baby) – Seizures during labour – Attendance at ED – Congenital anomalies (neural tube defects (spina bifida), limb defects (club foot), cleft lip and palette etc) • Neurodevelopmental outcomes (Griffith Mental Development Scales and the Bayley Scales of Infant and Toddler Development scale)
Study design	<ul style="list-style-type: none"> • RCTs • Systematic reviews of RCTs • Published NMAs and IPDs will be considered for inclusion <p>If insufficient RCT evidence is available, prospective observational comparative studies will be considered only if they adjust for key confounders of the age of epilepsy onset, classification (focal, generalised or epilepsy syndrome).</p>

1 1.1.3. Methods and process

2 This evidence review was developed using the methods and process described in
3 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
4 described in the review protocol in appendix A and the methods document.

5 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

6 1.1.4. Effectiveness evidence

7 1.1.4.1. Included studies

8 A search was conducted for randomised controlled trials comparing therapeutic monitoring to
9 usual care, in which any necessary dose adjustments are made without knowledge of anti-
10 seizure medication levels.

11 One Health Technology Assessment (comprising a randomised trial nested within a cohort
12 study and a qualitative study) was included in the review.¹⁵¹ Only data from the randomised

1 trial component of the study were extracted. The randomised trial is summarised in Table 2
2 below. Evidence from the trial is summarised in the clinical evidence summary below (Table
3 3). See also the study selection flow chart in Appendix C, study evidence tables in Appendix
4 D, forest plots in Appendix E and GRADE tables in Appendix F.

5 **1.1.4.2. Excluded studies**

6 See the excluded studies list in Appendix J.

7

1 1.1.5. Summary of studies included in the effectiveness evidence

2 Table 2: Summary of studies included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Thangaratinam 2018 UK	Therapeutic drug monitoring (n=130) versus clinical features monitoring (n=133)	Pregnant women of < 24 weeks gestation with a confirmed diagnosis of epilepsy, on monotherapy (lamotrigine, carbamazepine, phenytoin or carbamazepine) or polytherapy (lamotrigine with either carbamazepine, phenytoin or levetiracetam), and with $\geq 25\%$ reduction in serum anti-seizure medication level at any time in pregnancy, compared with baseline or pre-pregnancy level.	Maternal mortality rate from randomisation to 6 weeks post-partum. Neonatal mortality rate. Rate of stillbirth from randomisation to end of pregnancy. Proportion of women who experienced no seizures from randomisation to 6 weeks post-partum. Time to first seizure from randomisation up to 6 weeks post-partum. Time to multiple seizures from randomisation up to 6 weeks post-partum. Mean daily dose of anti-seizure medication: monotherapy with carbamazepine, levetiracetam or lamotrigine, or polytherapy with lamotrigine and levetiracetam, from randomisation to 6 weeks post-partum.	One woman received phenytoin monotherapy and one woman received lamotrigine polytherapy with carbamazepine. No between-group comparisons were possible for these anti-seizure medication regimens. Participants were monitored for serum anti-seizure medication levels from baseline until 6 to 8 weeks post-partum. The time-period of observation for neonatal mortality was not stated. It was assumed to be from randomisation to 28 days after a live birth, in keeping with the established definition of the neonatal period. Period of observation for rate of admission to neonatal unit was not stated but assumed to be from randomisation to 4 weeks post-partum.

Study	Intervention and comparison	Population	Outcomes	Comments
			<p>Quality of life (QOLIE-31 and QOLIE-31 Overall Health) from randomisation to 36 weeks gestation.</p> <p>Quality of life (EQ-5D) from randomisation to 6 weeks post-partum.</p> <p>Maternal admission to HDU/ICU from randomisation to 6 weeks post-partum.</p> <p>Rate of admission to neonatal unit.</p> <p>Rate of major congenital malformation from randomisation to 6 weeks post-partum.</p>	

1 See Effectiveness evidence for full evidence tables.

2 **1.1.6. Summary of the effectiveness evidence**

3 **Table 3: Clinical evidence summary: therapeutic drug monitoring versus clinical features monitoring**

Outcomes	No of Participants Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Therapeutic drug monitoring versus clinical features monitoring (95% CI)
Quality of life (QOLIE-31 Overall Health)	225 Randomisation to 36 weeks gestation	LOW ^{a,b} due to risk of bias		The mean quality of life (QOLIE-31 Overall Health) in the control group was 7.3	The mean quality of life (QOLIE-31 Overall Health) in the intervention group was 0.35 lower (0.72 lower to 0.02 higher).

Quality of life (QOLIE-31)	224 Randomisation to 36 weeks gestation	LOW ^{a,c} due to risk of bias		The mean quality of life (QOLIE-31) in the control group was 73.7	The mean quality of life (QOLIE-31) in the intervention groups was 2.5 lower (5.1 lower to 0.1 higher).
Quality of life (EQ-5D)	201 Randomisation to 6 weeks post- partum	LOW ^{d,e} due to risk of bias		The mean quality of life (EQ- 5D) in the control group was 0.9	The mean quality of life (EQ-5D) in the intervention groups was no higher or lower (0.05 lower to 0.05 higher).
Risk of first seizure	257 Randomisation to 6 weeks post- partum	VERY LOW ^{a,f} due to risk of bias, imprecision	HR 0.8 (0.55 to 1.16)	Not available	RD not calculable
Risk of multiple seizures	257 Randomisation to 6 weeks post- partum	VERY LOW ^{a,g} due to risk of bias, imprecision	HR 1.4 (0.73 to 2.68)	Not available	RD not calculable
Seizure freedom	257 Randomisation to 6 weeks post- partum	LOW ^{a,f} due to risk of bias	RR 1.01 (0.83 to 1.22)	615 per 1000	6 more per 1000 (from 105 fewer to 135 more)
Maternal mortality	263 Randomisation to 6 weeks post- partum	LOW ^{h,n} due to risk of bias, imprecision			RD 0.00 (-0.01 to 0.01)
Maternal admission to HDU/ICU	257 Randomisation to 6 weeks post- partum	VERY LOW ^{g,h} due to risk of bias, imprecision	OR 1.8 (0.41 to 7.9)	23 per 1000	

Mean daily carbamazepine exposure (monotherapy)	36	VERY LOW ^{hi} due to risk of bias, imprecision		The mean daily carbamazepine exposure (monotherapy) in the control group was 695 mg	The mean daily carbamazepine exposure (monotherapy) in the intervention group was 12.1 lower (226.7 lower to 202.5 higher)
Mean daily lamotrigine exposure (monotherapy)	138	LOW ^{hi} due to risk of bias, imprecision		The mean daily lamotrigine exposure (monotherapy) in the control group was 252.6 mg	The mean daily lamotrigine exposure (monotherapy) in the intervention group was 32.3 higher (14.4 lower to 79 higher)
Mean daily levetiracetam exposure (monotherapy)	62	LOW ^{hk} due to risk of bias, imprecision		The mean daily levetiracetam exposure (monotherapy) in the control group was 1628.5 mg	The mean daily levetiracetam exposure (monotherapy) in the intervention group was 166.5 higher (229.8 lower to 562.8 higher)
Mean daily levetiracetam exposure (in women on levetiracetam plus lamotrigine polytherapy)	25	VERY LOW ^{hi} due to risk of bias, imprecision		The mean daily levetiracetam exposure (women on levetiracetam plus lamotrigine polytherapy) in the control group was 2122.2 mg	The mean daily levetiracetam exposure (women on levetiracetam plus lamotrigine polytherapy) in the intervention group was 137.3 lower (945.9 lower to 671.3 higher)
Mean daily lamotrigine exposure (in women on levetiracetam plus lamotrigine polytherapy)	25	LOW ^{hm} due to risk of bias, imprecision		The mean daily lamotrigine exposure (women on levetiracetam plus lamotrigine polytherapy) in the control group was 413.8 mg	The mean daily lamotrigine exposure (women on levetiracetam plus lamotrigine polytherapy) in the intervention group was 97.4 higher (28.7 lower to 223.5 higher)
Stillbirth	259	VERY LOW ^{gh} due to risk of bias, imprecision	Peto OR 0.14 (0.01 to 2.31)	15 per 1000	13 fewer per 1000 (from 15 fewer to 19 more)
Neonatal mortality	260	LOW ^{hn} due to risk of bias, imprecision			RD 0.0 (-0.01 to 0.01)

Major congenital malformation	259	VERY LOW ^{gh} due to risk of bias, imprecision	OR 0.66 (0.23 to 1.89)	75 per 1000	
Admission to Neonatal Intensive Care Unit	259	VERY LOW ^{gh} due to risk of bias, imprecision	OR 1.6 (0.29 to 8.83)	134 per 1000	

^a There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome.

^b MID for this outcome was calculated as ± 0.8 .

^c The MID for this outcome was ± 6.75 .

^d There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome. There was a high but similar rate of attrition in both groups.

^e The MID for this outcome was ± 0.09 .

^f The MID for this outcome was 0.8 and 1.25.

^g The MID for this outcome was 0.8 and 1.25. The outcome was downgraded by 2 increments as the confidence interval crossed both MIDs.

^h There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias.

ⁱ The MID for this outcome was ± 168.2 . The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

^j The MID for this outcome was ± 74.0 . The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

^k The MID for this outcome was ± 463.25 . The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

^l The MID for this outcome was ± 538.75 . The outcome was downgraded by 2 increments as the confidence interval crossed both MIDs.

^m The MID for this outcome was ± 45.55 . The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

ⁿ Downgraded by 1 increment as the outcome is from a single study with zero events in both arms, and sample size >70 and <350 .

1 **Table 4: Clinical evidence summary: therapeutic drug monitoring versus clinical features monitoring**

2 See Appendix F for full GRADE tables.

3

1

2 1.1.7. Economic evidence

3 1.1.7.1. Included studies

4 No health economic studies were included.

5 1.1.7.2. Excluded studies

6 No relevant health economic studies were excluded due to assessment of limited
7 applicability or methodological limitations.

8 See also the health economic study selection flow chart in Appendix G.

9 1.1.8. Economic model

10 This area was not prioritised for a new cost-effectiveness analysis.

11 1.1.9. Unit costs

12 Relevant unit costs are provided below to aid consideration of cost-effectiveness.

13 Cost of staff time

Resource	Unit costs
Hospital-based nurse, Band 6: Cost per hour	£53
Hospital-based doctor, Speciality registrar: Cost per hour	£58

14 *Source: PSSRU 2020¹, including qualification costs*

15 Cost of test for therapeutic drug monitoring

16 Therapeutic drug monitoring can be conducted by epilepsy centres internally if they have the
17 appropriate resources. In addition, epilepsy centres that can undertake testing internally can
18 also charge for these tests if they are requested externally.

19 The unit costs provided are illustrative of the costs observed for one epilepsy centre and
20 indicate the cost of external testing for those epilepsy centres that are unable to provide
21 therapeutic drug monitoring through use of internal resources.

Resource	Internal testing	External testing
Cost of tests for Lamotrigine, Phenytoin, and Carbamazepine	£9.50	£12.50
Levetiracetam	£22.50	£30

22 *Source: Guideline Committee member*

23 1.1.10. Committee's discussion and interpretation of the evidence

24 1.1.10.1. The outcomes that matter most

25 The selection of outcomes in the protocol reflected concern that physiological changes
26 during pregnancy can have a marked effect on the serum concentrations of ASMs, that
27 deterioration in seizure control can be harmful to both the mother and foetus, and that there
28 are foetal risks associated with exposure to ASMs. The outcomes comprised: mortality of
29 mother or baby at study follow-up, seizure freedom during pregnancy and at six months post-
30 partum, reduction in seizure frequency (50% or more), time to first seizure in pregnancy and

1 up to up to six weeks post-partum, time to subsequent seizures (within an observation period
2 of up to one year), ASM exposure (mean daily), and quality of life (using any validated
3 measures) at study follow-up. Also included were the following adverse events: ASM toxicity,
4 pregnancy complications in the mother or baby (maternal admission to a high dependency or
5 intensive care unit or admission of the baby to a neonatal intensive care unit), seizures
6 during labour, attendance at an emergency department, congenital anomalies, and
7 neurodevelopmental outcomes.

8 There was no evidence found for the following outcomes: reduction in seizure frequency,
9 ASM toxicity, seizures during labour and neurodevelopmental impairment.

10 1.1.10.2. **The quality of the evidence**

11 Evidence was provided by a single randomised controlled trial of therapeutic drug monitoring
12 (TDM) versus clinical features monitoring (CFM) among women under 24 weeks gestation in
13 whom ASM concentrations had fallen by 25% or more. In the TDM group, monthly ASM
14 concentrations were communicated to the responsible clinician. In the CFM group, the
15 mother and responsible clinician were unaware of the ASM concentrations. The quality of
16 evidence for protocol-specified outcomes ranged from low to very low. This was due to risk of
17 bias and low precision. The risk of bias arose from a lack of clarity about allocation
18 concealment and a lack of blinding among outcome assessors. Low precision arose from a
19 failure to recruit the target number of participants. Four outcomes were reasonably precise:
20 quality of life measured using QOLIE-31 and QOLIE-31 (Overall Health) favoured CFM
21 rather than TDM, but the effects were very small; and neither quality of life measured using
22 EQ-5D nor seizure freedom differed between TDM and monitoring based on clinical features
23 alone. The committee noted that the control (CFM) group had background measurement of
24 ASM concentrations, and that clinicians managing the care of those women made dosing
25 decisions in the knowledge that those measurements could be revealed in certain
26 circumstances. These circumstances included, for example, if levels were found to be above
27 the therapeutic range with risks of toxicity. Knowledge of the background drug levels for the
28 control group could potentially underestimate any benefit observed by performing therapeutic
29 drug monitoring. Some discrepancies in the reporting of the study were also highlighted. For
30 example, the mean ASM exposures in each group for women on both levetiracetam and
31 lamotrigine appear to have been entered in reverse order. This impacted the confidence of
32 the committee in making recommendations based on this trial. It was agreed that the trial
33 was inconclusive, neither providing clear evidence in favour of TDM in pregnancy, nor
34 providing clear evidence against it. A research recommendation was therefore made for
35 further study to address the clinical and cost effectiveness of decisions about TDM in girls,
36 young women, and women with epilepsy.

37 No evidence was found for drug monitoring in women or girls pre-conception or in the post-
38 partum period beyond 6 weeks.

39 1.1.10.3. **Benefits and harms**

40 The committee agreed that there was no clinically important difference seen in any of the
41 included outcomes. For most outcomes, this was because of a lack of precision, a risk of
42 bias, or both.

43
44 There were, however, four outcomes with reasonably precise estimates. Quality of life
45 measured on the QOLIE-31 scale (maximum score 100) yielded an adjusted mean difference
46 of 2.5 points lower with TDM, with a 95% confidence interval of 5.1 lower to 0.1 higher. This
47 most likely indicates better quality of life with clinical features monitoring, but by a very small
48 amount of 5.1 points at best. Quality of life measured on the overall health item of the
49 QOLIE-31 scale (maximum score 10) yielded an adjusted mean difference of 0.35 points
50 lower with TDM, with a 95% confidence interval of 0.72 points lower to 0.02 points higher.
51 Again, this potentially indicates better quality of life with CFM, but by a very small degree.
52 Quality of life measured on the EQ5-D scale (maximum score 1) showed no difference

1 between groups (adjusted mean difference 0.0, 95% confidence interval -0.05 to 0.05). The
2 effect (if any) was therefore very small and of indeterminate direction. Lastly, the proportion
3 of women without any seizures over the whole period of observation was similar in each
4 group, yielding an absolute risk difference of only six more women per thousand in the TDM
5 group. The maximum and minimum plausible values (105 women fewer to 135 women more)
6 could be clinically important, but the point estimate suggests very little difference, and the
7 direction of effect (if any) was unclear.

8
9 The committee agreed to reflect MHRA safety advice on monitoring of ASMs in pregnancy in
10 their recommendations. However, given the limited and inconclusive evidence included in
11 this review, the committee felt a research recommendation was needed to encourage more
12 research in this area.

13
14 The committee highlighted the importance of obtaining preconception levels of antiseizure
15 medication as a baseline level to compare and titrate against when monitoring drug levels
16 during pregnancy. Where preconception levels were not possible, the committee
17 recommended using levels recorded as early as possible in pregnancy. The committee
18 agreed informal consensus recommendations were needed to ensure the preference of the
19 women and girls was considered, that adequate information for the care of women and girls
20 with epilepsy who are pregnant is accessible to all the healthcare teams involved.
21 Furthermore, more frequent monitoring should be offered to vulnerable groups i.e., women
22 and girls with learning disabilities, under the age of 16 years, with active epilepsy (a seizure
23 within the past 12 months) and/or who have bilateral tonic-clonic seizures. The committee
24 agreed, the care of women and girls who are pregnant, or planning pregnancy should be
25 within an epilepsy specialist team, who can provide advice on any adjustments to the ASM
26 prescribed. They also noted the importance of providing advice on not stopping medication
27 without first discussing with a clinician.

28
29 The committee highlighted questions or concerns often raised about breastfeeding after the
30 birth. They agreed published data is limited but has shown the amount of drugs in breast milk
31 is extremely small and has not demonstrated any harm to the baby. They agreed that the
32 advantages of breastfeeding outweighed any small risk of the drug affecting the baby.

33 1.1.10.4. Cost effectiveness and resource use

34 No health economic evidence was identified for this review question. The committee agreed
35 that current practice is not consistent nationally with regards to therapeutic drug monitoring
36 pre-conception and during pregnancy. In some centres, women will have their drug levels
37 assessed pre-conception and then receive regular monitoring throughout their pregnancy.
38 Conversely, in other centres drug monitoring is rarely or never done. The drug levels are
39 measured through blood tests. The committee noted that for some of the drugs, the tests
40 need to be sent away at high cost and take time to come back limiting their clinical value. It
41 was thought that most centres would be able to obtain concentrations of levetiracetam,
42 lamotrigine, carbamazepine, phenytoin, phenobarbitone and sodium valproate within a
43 reasonable time frame.

44 The committee noted that monitoring should typically be conducted three months prior to
45 actively trying to conceive and once the dosage of ASMs are stable. An additional
46 appointment would then be required once a person has conceived. Subsequent monitoring is
47 then dependent on how the initial ASM concentration compares to pre-conception dosing. If
48 the ASM concentration has not changed, monitoring may only be undertaken once per
49 trimester. However, if the ASM concentration has dropped substantially, therapeutic drug
50 monitoring is required more frequently.

1 Because therapeutic drug monitoring is variable in current practice, the committee concluded
2 it was difficult to determine which health care professional would typically undertake
3 therapeutic drug monitoring in current practice. However, the committee noted that
4 therapeutic drug monitoring would likely either be undertaken by an epilepsy nurse or doctor.
5 The cost of an epilepsy nurse is £53 per hour, and the cost of a doctor is £58 per hour.
6 Therefore, assuming a 15-minute appointment, the cost of staff time for monitoring per
7 appointment is £13.25 and £14.50, respectively. The overall cost of monitoring based on the
8 unit costs provided indicates that monitoring would cost between £23.00 - £44.50 per
9 monitoring appointment.

10 The committee made recommendations which are in line with the MHRA safety advice on
11 monitoring in pregnancy. Because there are a proportion of people who do not currently
12 receive therapeutic drug monitoring there may be an increase in drug monitoring compared
13 to current practice.

14 **1.1.10.5. Other factors the committee took into account**

15 The committee discussed the current MHRA guidance that includes advice to monitor
16 lamotrigine concentration before, during, and after pregnancy (including shortly after birth), to
17 ensure appropriate clinical management of pregnant women treated with levetiracetam, to
18 'consider' monitoring concentrations of the active metabolite of oxcarbazepine (including
19 postpartum if the dose was changed during pregnancy), and that monitoring of phenytoin
20 concentrations may be valuable as a guide to appropriate adjustment of dosage. The
21 committee decided, therefore to make a recommendation to monitor drug levels in women or
22 girls who are planning a pregnancy or are pregnant and prescribed these particular ASMs in
23 line with guidance provided by the MHRA guidance and also given in the BNF. It was noted
24 that routine care already includes more frequent monitoring of women and girls who are
25 pregnant if they are under the age of sixteen, have very active epilepsy, have bilateral tonic-
26 clonic seizure or have learning disabilities. For further discussion of MHRA guidance, see
27 evidence review F Safety of ASM in women and girls.

28
29 The committee also discussed the [MBRRACE-UK 2019 report 'Saving Lives, Improving
30 Mothers' Care'](#) which highlighted that maternal deaths have occurred after ASM
31 concentrations have been monitored but not subsequently acted upon. This was of
32 considerable concern to the committee who agreed that were an ASM level to be checked, it
33 was essential that level was checked and acted on appropriately.

34
35 The committee considered that there is variation in practice with the recommendations
36 reflecting current practice in some areas but not in others. They agreed that risk perceptions
37 differ among clinicians, and that ASM prescribing also varies across healthcare settings.
38 These can all influence the advice given to women and girls and their experience of care.
39 These variations make it difficult to make judgements about resource impact.

40 **1.1.11. Recommendations supported by this evidence review**

41 This evidence review supports recommendations 4.6.1 – 4.6.10 and a research
42 recommendation on therapeutic drug monitoring in women and girls in the NICE guideline.
43

References

1. Curtis L, Burns A. Unit costs of health and social care 2020. Canterbury. Personal Social Services Research Unit University of Kent, 2020. Available from: <https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/>
2. Helde G, Bovim G, Brathen G, Brodtkorb E. A structured, nurse-led intervention program improves quality of life in patients with epilepsy: a randomized, controlled trial. *Epilepsy & Behavior*. 2005; 7(3):451-457
3. Islamiyah WR, Suharjono, Jaya HP, Ernawati I. Analysis relationship of self-medication card administration with adherence (ARMS score), phenytoin serum levels and frequency of seizures in patients using phenytoin monotherapy. *Research Journal of Pharmacy and Technology*. 2019; 12(12):5991-6000
4. Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. *Drugs in R & D*. 2016; 16(4):303-316
5. Jacob S, Nair AB, Shah J. Revisiting clinical practice in therapeutic drug monitoring of first-generation antiepileptic drugs. *Drugs and Therapy Perspectives*. 2019; 35(10):500-517
6. Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. *The Italian TDM Study Group in Epilepsy. Epilepsia*. 2000; 41(2):222-230
7. Jarvie D, Mahmoud SH. Therapeutic drug monitoring of levetiracetam in select populations. *Journal of Pharmacy & Pharmaceutical Sciences*. 2018; 21(1S):149s-176s
8. Jimenez M, Grau-Lopez L, Ciurans J, Garcia-Esperon C, Fumanal A, Barambio S et al. Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. *Neurologia*. 2020; S0213-4853(20):30135-30133
9. Johannessen SI, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. *Expert Review of Neurotherapeutics*. 2008; 8(6):929-939
10. Kelly TE. Teratogenicity of anticonvulsant drugs. I: Review of the literature. *American Journal of Medical Genetics*. 1984; 19(3):413-434
11. Kim K, Magness JW, Nelson R, Baron V, Brixner DI. Clinical utility of pharmacogenetic testing and a clinical decision support tool to enhance the identification of drug therapy problems through medication therapy management in polypharmacy patients. *Journal of Managed Care and Specialty Pharmacy*. 2018; 24(12):1251-1259
12. Koch S, Göpfert-Geyer I, Jäger-Roman E, Jakob S, Huth H, Hartmann A et al. Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development. *Deutsche medizinische wochenschrift (1946)*. 1983; 108(7):250-257
13. Kusznir Vitturi B, Barreto Cabral F, Mella Cukiert C. Outcomes of pregnant women with refractory epilepsy. *Seizure*. 2019; 69:251-257
14. Larkin JG, McGuire GM, Percy-Robb I, Brodie MJ. Anticonvulsant monitoring at the epilepsy clinic: A prospective study. *British Journal of Clinical Pharmacology*. 1988; 25(5):627P-628P

- 1 15. Leenen LAM, Wijnen BFM, Kessels AGH, Chan H, de Kinderen RJA, Evers S et al.
2 Effectiveness of a multicomponent self-management intervention for adults with
3 epilepsy (ZMILE study): A randomized controlled trial. *Epilepsy & Behavior*. 2018;
4 80:259-265
- 5 16. Lhatoo SD, Johnson AL, Goodridge DM, MacDonald BK, Sander JW, Shorvon SD.
6 Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of
7 a long-term, prospective, population-based cohort. *Annals of Neurology*. 2001;
8 49(3):336-344
- 9 17. Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy. *Annals of*
10 *Pharmacotherapy*. 2009; 43(10):1692-1695
- 11 18. Losada-Camacho M, Guerrero-Pabon MF, Garcia-Delgado P, Martinez-Martinez F.
12 Impact of a pharmaceutical care programme on health-related quality of life among
13 women with epilepsy: a randomised controlled trial (IPHIWWE study). *Health &*
14 *Quality of Life Outcomes*. 2014; 12:162
- 15 19. Maguire M, Jackson C, Marson A, Nevitt S. Treatments for the prevention of Sudden
16 Unexpected Death in Epilepsy (SUDEP). *Cochrane Database of Systematic Reviews*
17 2016, Issue 7. Art. No.: CD011792. DOI: 10.1002/14651858.CD011792.pub2.
- 18 20. Mauri Llerda JA, Suller Marti A, de la Pena Mayor P, Martinez Ferri M, Poza Aldea
19 JJ, Gomez Alonso J et al. The Spanish Society of Neurology's official clinical practice
20 guidelines for epilepsy. Special considerations in epilepsy: comorbidities, women of
21 childbearing age, and elderly patients. *Neurologia*. 2015; 30(8):510-517
- 22 21. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age:
23 pharmacokinetic considerations. *Clinical Pharmacokinetics*. 2002; 41(8):559-579
- 24 22. Mehrotra TN, Aneja GK, Arora V, Goel S, Singh VS. Valproate sodium in epilepsy. A
25 clinical trial including monitoring of drug levels. *Journal of the Association of*
26 *Physicians of India*. 1990; 38(4):277-279
- 27 23. Mikov S, Gjergja Juraski R, Fuhic A, Bonjak Paic M, Ivihevic Bakulic T, Cvitanovic-
28 ojat LJ et al. Prospective surveillance of croatian pregnant women under lamotrigine
29 monotherapy--aspects of pre-pregnancy counseling and drug monitoring. *Acta Clinica*
30 *Croatica*. 2010; 49(Suppl 2):99
- 31 24. Miskov S, Gjergja-Juraski R, Cvitanovic-Sojat L, Bakulic TI, Fucic A, Bosnjak-Pasic M
32 et al. Prospective surveillance of Croatian pregnant women on lamotrigine
33 monotherapy--aspects of pre-pregnancy counseling and drug monitoring. *Acta Clinica*
34 *Croatica*. 2009; 48(3):271-281
- 35 25. National Institute for Health and Care Excellence. Developing NICE guidelines: the
36 manual [updated October 2020]. London. National Institute for Health and Care
37 Excellence, 2014. Available from:
38 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 39 26. Nilsson L, Bergman U, Diwan V, Farahmand BY, Persson PG, Tomson T.
40 Antiepileptic drug therapy and its management in sudden unexpected death in
41 epilepsy: a case-control study. *Epilepsia*. 2001; 42(5):667-673
- 42 27. Nonoda Y, Iwasaki T, Ishii M. The efficacy of gabapentin in children of partial seizures
43 and the blood levels. *Brain and Development*. 2014; 36(3):194-202
- 44 28. Otani K. Risk factors for the increased seizure frequency during pregnancy and
45 puerperium. *Folia Psychiatrica et Neurologica Japonica*. 1985; 39(1):33-41

- 1 29. Pack AM. Therapy Insight: Clinical management of pregnant women with epilepsy.
2 Nature Clinical Practice Neurology. 2006; 2(4):190-200
- 3 30. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI et al.
4 Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a
5 position paper by the subcommission on therapeutic drug monitoring, ILAE
6 Commission on Therapeutic Strategies. *Epilepsia*. 2008; 49(7):1239-1276
- 7 31. Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic
8 drugs in epilepsy: A 2018 update. *Therapeutic Drug Monitoring*. 2018; 40(5):526-548
- 9 32. Pennell PB. 2005 AES annual course: evidence used to treat women with epilepsy.
10 *Epilepsia*. 2006; 47(Suppl 1):46-53
- 11 33. Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs
12 seem to be safest? *Epilepsia*. 2008; 49(Suppl 9):43-55
- 13 34. Pennell PB. Pregnancy in women who have epilepsy. *Neurologic Clinics*. 2004;
14 22(4):799-820
- 15 35. Pennell PB. Use of antiepileptic drugs during pregnancy: Evolving concepts.
16 *Neurotherapeutics*. 2016; 13(4):811-820
- 17 36. Pennell PB, French JA, Harden CL, Davis A, Bagiella E, Andreopoulos E et al.
18 Fertility and birth outcomes in women with epilepsy seeking pregnancy. *JAMA*
19 *Neurology*. 2018; 75(8):962-969
- 20 37. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK et al. Lamotrigine
21 in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.
22 *Neurology*. 2008; 70(22 Pt 2):2130-2136
- 23 38. Perucca E. Current trends in antiepileptic drug therapy. *Epilepsia*. 2003; 44(Suppl
24 4):41-47
- 25 39. Pirie DA, Al Wattar BH, Pirie AM, Houston V, Siddiqua A, Doug M et al. Effects of
26 monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis.
27 *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 2014;
28 172:26-31
- 29 40. Plumpton CO, Brown I, Reuber M, Marson AG, Hughes DA. Economic evaluation of a
30 behavior-modifying intervention to enhance antiepileptic drug adherence. *Epilepsy &*
31 *Behavior*. 2015; 45:180-186
- 32 41. Pulliam C, Pait L, Winslow J. How to give phenytoin safely. Report from a long-term
33 care facility in North Carolina. *North Carolina Medical Journal*. 1996; 57(5):292-295
- 34 42. Rahmathullah L, Underwood BA, Thulasiraj RD, Milton RC, Ramaswamy K,
35 Rahmathullah R et al. Reduced mortality among children in southern India receiving a
36 small weekly dose of vitamin A. *New England Journal of Medicine*. 1990;
37 323(14):929-935
- 38 43. Rajadhyaksha S, Shah KN, Kanhere S, Naik N, Mehta R. Does treatment change the
39 outcome of seizures and computerized tomographic lesions in intracranial
40 granulomas? *Journal of Tropical Pediatrics*. 1999; 45(3):161-165
- 41 44. Raju GB, Behari M, Prasad K, Ahuja GK. Randomized, double-blind, placebo-
42 controlled, clinical trial of D-alpha-tocopherol (vitamin E) as add-on therapy in
43 uncontrolled epilepsy. *Epilepsia*. 1994; 35(2):368-372
- 44 45. Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, Willis J et al.
45 Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and

- 1 tolerability. First International Vagus Nerve Stimulation Study Group. *Epilepsia*. 1994;
2 35(3):627-636
- 3 46. Rashid MR, Najeeb R, Mushtaq S, Habib R. Comparative evaluation of midazolam,
4 dexmedetomidine, and propofol as Intensive Care Unit sedatives in postoperative
5 electively ventilated eclamptic patients. *Journal of Anaesthesiology Clinical
6 Pharmacology*. 2017; 33(3):331-336
- 7 47. Rath W, Fischer T. The diagnosis and treatment of hypertensive disorders of
8 pregnancy: New findings for antenatal and inpatient care. *Deutsches Arzteblatt*. 2009;
9 106(45):733-738
- 10 48. Reardon DA, Lassman AB, Van Den Bent M, Kumthekar P, Merrell R, Scott AM et al.
11 Efficacy and safety results of ABT-414 in combination with radiation and
12 temozolomide in newly diagnosed glioblastoma. *Neuro-Oncology*. 2017; 19(7):965-
13 975
- 14 49. Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial
15 of botulinum toxin injections into the salivary glands to reduce drooling in children with
16 neurological disorders. *Developmental Medicine and Child Neurology*. 2008;
17 50(2):123-128
- 18 50. Rektor I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A et al. Assessment of
19 the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures:
20 Analysis of four open-label extension studies. *Epilepsia*. 2020; 61(7):1491-1502
- 21 51. Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of
22 refractory epilepsy. *British Journal of Clinical Pharmacology*. 1989; 27(Suppl 1):125S-
23 129S
- 24 52. Rentmeester T, Janssen A, Hulsman J, Scholtes F, van der Kleij B, Overweg J et al.
25 A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole
26 as add-on therapy in patients with uncontrolled partial seizures. *Epilepsy Research*.
27 1991; 9(1):59-64
- 28 53. Rentmeester T, Janssen A, Hulsman J, Scholtes F, van der Kleij B, Overweg J et al.
29 Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in
30 patients with uncontrolled partial seizures: a 1-year open follow-up. *Epilepsy
31 Research*. 1991; 9(1):65-70
- 32 54. Rezaei F, Nasser K, Esfandiari GR, Sadeghi SM, Fathie M, Gharibi F. Remifentanyl
33 added to propofol for induction of anesthesia can reduce reorientation time after
34 electroconvulsive therapy in patients with severe mania. *Journal of ECT*. 2012;
35 28(2):124-127
- 36 55. Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ et al. Transcatheter patent
37 foramen ovale closure versus medical therapy for cryptogenic stroke: A meta-analysis
38 of randomized clinical trials. *BMC Cardiovascular Disorders*. 2013; 13:116
- 39 56. Rich TL, Menk J, Krach LE, Feyma T, Gillick BT. Repetitive transcranial magnetic
40 stimulation/behavioral intervention clinical trial: Long-term follow-up of outcomes in
41 congenital hemiparesis. *Journal of Child and Adolescent Psychopharmacology*. 2016;
42 26(7):598-605
- 43 57. Richardson MP, Koepp MJ, Brooks DJ, Duncan JS. 11C-flumazenil PET in
44 neocortical epilepsy. *Neurology*. 1998; 51(2):485-492
- 45 58. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of
46 sodium valproate and carbamazepine in adult onset epilepsy. *Journal of Neurology,
47 Neurosurgery and Psychiatry*. 1994; 57(6):682-687

- 1 59. Ridsdale L, Kwan I, Cryer C. Newly diagnosed epilepsy: can nurse specialists help?
2 A randomized controlled trial. *Epilepsy Care Evaluation Group. Epilepsia*. 2000;
3 41(8):1014-1019
- 4 60. Ridsdale L, McKinlay A, Wojewodka G, Robinson EJ, Mosweu I, Feehan SJ et al.
5 Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]:
6 a randomised controlled trial. *Health technology assessment (Winchester, England)*.
7 2018; 22(21):1-142
- 8 61. Ridsdale L, Robins D, Cryer C, Williams H. Feasibility and effects of nurse run clinics
9 for patients with epilepsy in general practice: randomised controlled trial. *Epilepsy*
10 *Care Evaluation Group. BMJ*. 1997; 314(7074):120-122
- 11 62. Ridsdale L, Wojewodka G, Robinson EJ, Noble AJ, Morgan M, Taylor SJC et al. The
12 effectiveness of a group self-management education course for adults with poorly
13 controlled epilepsy, SMILE (UK): A randomized controlled trial. *Epilepsia*. 2018;
14 59(5):1048-1061
- 15 63. Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP et al.
16 Treatment de-escalation after mitoxantrone therapy: Results of a phase IV,
17 multicentre, open-label, randomized study of subcutaneous interferon beta-1a in
18 patients with relapsing multiple sclerosis. *Therapeutic Advances in Neurological*
19 *Disorders*. 2012; 5(1):3-12
- 20 64. Ring H, Howlett J, Pennington M, Smith C, Redley M, Murphy C et al. Training nurses
21 in a competency framework to support adults with epilepsy and intellectual disability:
22 the EpAID cluster RCT. *Health Technology Assessment*. 2018; 22(10):1-104
- 23 65. Riveau G, Schacht AM, Dompnier JP, Deplanque D, Seck M, Waucquier N et al.
24 Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3
25 randomized, controlled trial in Senegalese children. *PLoS Neglected Tropical*
26 *Diseases*. 2018; 12:e0006968
- 27 66. Rivera-Castano L, Leal-Cantu R, Abreu P, Guerrero M, Davila G. A 21-week open-
28 label clinical trial of pregabalin as adjunctive therapy in partial seizures at multiple
29 centers in Mexico (PREPS Mexico). *Epilepsy Research*. 2012; 100(1-2):74-79
- 30 67. Robinson BJ, Robinson GM, Maling TJ, Johnson RH. Is clonidine useful in the
31 treatment of alcohol withdrawal? *Alcoholism: Clinical & Experimental Research*. 1989;
32 13(1):95-98
- 33 68. Rogin J, Wheless J, Abou-Khalil B, Wolter KD, Pixton GC, Sherman NA et al. Safety
34 and effectiveness of long-term treatment with diazepam auto-injector administered by
35 caregivers in an outpatient setting for the treatment of acute repetitive seizures.
36 *Epilepsia*. 2014; 55(9):1444-1451
- 37 69. Romo ML, Wyka K, Carpio A, Leslie D, Andrews H, Bagiella E et al. The effect of
38 albendazole treatment on seizure outcomes in patients with symptomatic
39 neurocysticercosis. *Transactions of the Royal Society of Tropical Medicine and*
40 *Hygiene*. 2015; 109(11):738-746
- 41 70. Rosati A, Ilvento L, L'Erario M, De Masi S, Biggeri A, Fabbro G et al. Efficacy of
42 ketamine in refractory convulsive status epilepticus in children: a protocol for a
43 sequential design, multicentre, randomised, controlled, open-label, non-profit trial
44 (KETASER01). *BMJ Open*. 2016; 6:e011565
- 45 71. Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R et al. Efficacy and
46 safety of perampanel in adolescent patients with drug-resistant partial seizures in
47 three double-blind, placebo-controlled, phase III randomized clinical studies and a

- 1 combined extension study. *European journal of paediatric neurology*: EJPN. 2015;
2 19(4):435-445
- 3 72. Rosman NP, Colton T, Labazzo J, Gilbert PL, Gardella NB, Kaye EM et al. A
4 controlled trial of diazepam administered during febrile illnesses to prevent recurrence
5 of febrile seizures. *New England Journal of Medicine*. 1993; 329(2):79-84
- 6 73. Rosman NP, Douglass LM, Paolini JL. Preventing febrile seizures in children with oral
7 diazepam: can a controlled trial truly be "double-blind?". *Journal of Pediatrics*. 2001;
8 138(4):548-552
- 9 74. Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and
10 pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A
11 phase II randomized study. *Neuro-Oncology*. 2014; 16(4):584-588
- 12 75. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine
13 with or without a booster dose in infants and children in Africa: final results of a phase
14 3, individually randomised, controlled trial. *Lancet*. 2015; 386(9988):31-45
- 15 76. RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Soulanoudjingar SS,
16 Fernandes JF, Aboosolo BP et al. First results of phase 3 trial of RTS,S/AS01 malaria
17 vaccine in African children. *New England Journal of Medicine*. 2011; 365(20):1863-
18 1875
- 19 77. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in
20 adults with uncontrolled focal epilepsy: results from a double-blind, randomized,
21 placebo-controlled trial. *Epilepsia*. 2014; 55(1):47-56
- 22 78. Sabers A, Moller A, Dam M, Smed A, Arlien-Soborg P, Buchman J et al. Cognitive
23 function and anticonvulsant therapy: effect of monotherapy in epilepsy. *Acta*
24 *Neurologica Scandinavica*. 1995; 92(1):19-27
- 25 79. Sabna M, Thomas A. Impact of pharmaceutical care on bone health in epileptic
26 women taking antiepileptic drugs: An interventional trial. *International Research*
27 *Journal of Pharmacy*. 2018; 9(7):173-176
- 28 80. Saccone G, Schuit E, Amer-Wahlin I, Xodo S, Berghella V. Electrocardiogram ST
29 analysis during labor: A systematic review and meta-analysis of randomized
30 controlled trials. *Obstetrics and Gynecology*. 2016; 127(1):127-135
- 31 81. Sacevich C, Semakuba B, McKay WP, Thakore S, Twagirumugabe T, Nyiligira J.
32 Subcutaneous ketamine for postoperative pain relief in Rwanda: a randomized
33 clinical trial. *Canadian Journal of Anaesthesia*. 2018; 65(2):170-177
- 34 82. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy:
35 controlled trial in patients with partial onset seizures. *Annals of Neurology*. 1992;
36 32(3):386-392
- 37 83. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset
38 seizures. *Epilepsia*. 1997; 38(3):294-300
- 39 84. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ et al.
40 Effects of stimulus intensity and electrode placement on the efficacy and cognitive
41 effects of electroconvulsive therapy. *New England Journal of Medicine*. 1993;
42 328(12):839-846
- 43 85. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, 3rd, Shellenberger MK.
44 Randomized, controlled clinical trial of zonisamide as adjunctive treatment for
45 refractory partial seizures. *Epilepsia*. 2004; 45(6):610-617

- 1 86. Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD et al.
2 Quinolone treatment for pediatric bacterial meningitis: a comparative study of
3 trovafloxacin and ceftriaxone with or without vancomycin. *Pediatric Infectious Disease*
4 *Journal*. 2002; 21(1):14-22
- 5 87. Sahjpal RL, Mahon J, Wiebe S. Dexamethasone for morbidity after subdural
6 electrode insertion--a randomized controlled trial. *Canadian Journal of Neurological*
7 *Sciences*. 2003; 30(4):340-348
- 8 88. Saida T, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Ueda K et al. Long-term efficacy
9 and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year
10 results of the phase 2 extension study. *BMC Neurology*. 2017; 17:17
- 11 89. Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy
12 volunteers: a double-blind, placebo-controlled trial. *Neurology*. 2010; 74(9):755-761
- 13 90. Salinsky MC. A randomized controlled trial of chronic vagus nerve stimulation for
14 treatment of medically intractable seizures. *Neurology*. 1995; 45(2):224-230
- 15 91. Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB. Vagus nerve
16 stimulation for the treatment of medically intractable seizures. Results of a 1-year
17 open-extension trial. Vagus Nerve Stimulation Study Group. *Archives of Neurology*.
18 1996; 53(11):1176-1180
- 19 92. Salloway S, Marshall GA, Lu M, Brashear HR. Long-term safety and efficacy of
20 bapineuzumab in patients with mild-to-moderate alzheimer's disease: A phase 2,
21 open-label extension study. *Current Alzheimer Research*. 2018; 15(13):1231-1243
- 22 93. Saposnik G, Cohen LG, Mamdani M, Pooyania S, Ploughman M, Cheung D et al.
23 Efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation
24 (EVREST): a randomised, multicentre, single-blind, controlled trial. *Lancet Neurology*.
25 2016; 15(10):1019-1027
- 26 94. Saygin MZ, Sungur MZ, Sabol EU, Cetinkaya P. Nefazodone versus sertraline in
27 treatment of posttraumatic stress disorder. *Klinik Psikofarmakoloji Bulteni*. 2002;
28 12(1):1-5
- 29 95. Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL et al.
30 Lamotrigine: A six-month, placebo-controlled, safety and tolerance study. *Journal of*
31 *Epilepsy*. 1995; 8(3):201-209
- 32 96. Schechtman G, Lind G, Winter J, Meyerson BA, Linderoth B. Intrathecal clonidine
33 and baclofen enhance the pain-relieving effect of spinal cord stimulation: A
34 comparative placebo-controlled, randomized trial. *Neurosurgery*. 2010; 67(1):173-181
- 35 97. Schonenberg M, Wiedemann E, Schneidt A, Scheeff J, Logemann A, Keune PM et al.
36 Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in
37 adults with attention-deficit hyperactivity disorder: a triple-blind, randomised,
38 controlled trial. *The Lancet Psychiatry*. 2017; 4(9):673-684
- 39 98. Schougaard LM, Mejdahl CT, Petersen KH, Jessen A, de Thurah A, Sidenius P et al.
40 Effect of patient-initiated versus fixed-interval telePRO-based outpatient follow-up:
41 study protocol for a pragmatic randomised controlled study. *BMC Health Services*
42 *Research*. 2017; 17(1):83
- 43 99. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for
44 treatment of prolonged seizures in childhood and adolescence: a randomised trial.
45 *Lancet*. 1999; 353(9153):623-626

- 1 100. Sedman AJ, Gilmet GP, Sayed AJ, Posvar EL. Initial human safety and tolerance
2 study of a GABA uptake inhibitor, CI-966: Potential role of GABA as a mediator in the
3 pathogenesis of schizophrenia and mania. *Drug Development Research*. 1990;
4 21(3):235-242
- 5 101. Seo JH, Lee YM, Lee JS, Kang HC, Kim HD. Efficacy and tolerability of the ketogenic
6 diet according to lipid:nonlipid ratios--comparison of 3:1 with 4:1 diet. *Epilepsia*. 2007;
7 48(4):801-805
- 8 102. Sethi A, Chandra D, Puri V, Mallika V. Gabapentin and lamotrigine in Indian patients
9 of partial epilepsy refractory to carbamazepine. *Neurology India*. 2002; 50(3):359-363
- 10 103. Seynaeve L, Devroye A, Dupont P, Van Paesschen W. Randomized crossover sham-
11 controlled clinical trial of targeted low-frequency transcranial magnetic stimulation
12 comparing a figure-8 and a round coil to treat refractory neocortical epilepsy.
13 *Epilepsia*. 2016; 57(1):141-150
- 14 104. Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N et al. BoTULS: A
15 multicentre randomized controlled trial to evaluate the clinical effectiveness and cost-
16 effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type
17 A. *Health Technology Assessment*. 2010; 14(26):i-141
- 18 105. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P et al.
19 Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine
20 comparison. *Archives of General Psychiatry*. 2006; 63(7):721-730
- 21 106. Shefner J, Meininger V, Rothstein J, Chio A, Ludolph A, Genge A et al. A double
22 blind, multi-national, placebo controlled trial of talampanel in amyotrophic lateral
23 sclerosis: study design and subject baseline characteristics. *Amyotrophic Lateral*
24 *Sclerosis*. 2009; 10(Suppl 1):72
- 25 107. Shi J, Zhou C, Liu S, Sun H, Wang Y, Yan F et al. Outcome impact of different
26 tranexamic acid regimens in cardiac surgery with cardiopulmonary bypass
27 (OPTIMAL): Rationale, design, and study protocol of a multicenter randomized
28 controlled trial. *American Heart Journal*. 2020; 222:147-156
- 29 108. Shim JY, Park YW, Yoon BH, Cho YK, Yang JH, Lee Y et al. Multicentre, parallel
30 group, randomised, single-blind study of the safety and efficacy of atosiban versus
31 ritodrine in the treatment of acute preterm labour in Korean women. *BJOG: An*
32 *International Journal of Obstetrics and Gynaecology*. 2006; 113(11):1228-1234
- 33 109. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind,
34 randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients
35 with refractory partial seizures. *Epilepsia*. 2000; 41(9):1179-1186
- 36 110. Si Y, Xiao X, Xia C, Guo J, Hao Q, Mo Q et al. Optimising epilepsy management with
37 a smartphone application: a randomised controlled trial. *Medical Journal of Australia*.
38 2020; 212(6):258-262
- 39 111. Simpson DM, Goldenberg J, Kasner S, Nash M, Reding MJ, Zweifler RM et al.
40 Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of
41 concept study. *Journal of Rehabilitation Medicine*. 2015; 47(10):924-931
- 42 112. Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole
43 therapy for neurocysticercosis in children: a randomized, placebo-controlled double
44 blind trial. *Pediatric Infectious Disease Journal*. 2003; 22(3):268-272
- 45 113. Singhi P, Kaushal M, Singhi S, Ray P. Seven days vs. 10 days ceftriaxone therapy in
46 bacterial meningitis. *Journal of Tropical Pediatrics*. 2002; 48(5):273-279

- 1 114. Singla M, Prabhakar S, Modi M, Medhi B, Khandelwal N, Lal V. Short-course of
2 prednisolone in solitary cysticercus granuloma: a randomized, double-blind, placebo-
3 controlled trial. *Epilepsia*. 2011; 52(10):1914-1917
- 4 115. Sivenius J, Ylinen A, Kalviainen R, Riekkinen PJ, Sr. Long-term study with
5 gabapentin in patients with drug-resistant epileptic seizures. *Archives of Neurology*.
6 1994; 51(10):1047-1050
- 7 116. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of
8 spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled
9 trial. US Tizanidine Study Group. *Neurology*. 1994; 44(11 Suppl 9):S34-42
- 10 117. Smith D, Chadwick D, Baker G, Davis G, Dewey M. Seizure severity and the quality
11 of life. *Epilepsia*. 1993; 34(Suppl 5):S31-S35
- 12 118. Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for
13 chronic sleep onset insomnia in children: a randomized placebo-controlled trial.
14 *Journal of Child Neurology*. 2001; 16(2):86-92
- 15 119. Sobaniec W, Kulak W, Smigielska-Kuzia J, Bockowski L, Majkowski J, Jedrzejczak J.
16 A multicenter, placebo-controlled, double-blind study of efficacy of a new form of
17 carbamazepine (Carbatrol) in refractory epileptic patients. *Polish Journal of*
18 *Pharmacology*. 2004; 56(2):195-201
- 19 120. Solanki C, Pandey P, Rao KV. Predictors of aneurysmal rebleed before definitive
20 surgical or endovascular management. *Acta Neurochirurgica*. 2016; 158(6):1037-
21 1044
- 22 121. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of
23 imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections.
24 *American Journal of Medicine*. 1985; 78(6A):85-91
- 25 122. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional
26 treatment for glioblastoma multiforme: A randomized, double-blind, placebo-
27 controlled trial. *Annals of Internal Medicine*. 2006; 144(5):337-343
- 28 123. Spivey WH, Roberts JR, Derlet RW. A clinical trial of escalating doses of flumazenil
29 for reversal of suspected benzodiazepine overdose in the emergency department.
30 *Annals of Emergency Medicine*. 1993; 22(12):1813-1821
- 31 124. Sprigg N, Flaherty K, Appleton JP, Salman RAS, Bereczki D, Beridze M et al.
32 Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an
33 international randomised, placebo-controlled, phase 3 superiority trial. *Lancet*. 2018;
34 391(10135):2107-2115
- 35 125. Srinivasakumar P, Zempel J, Trivedi S, Wallendorf M, Rao R, Smith B et al. Treating
36 EEG seizures in hypoxic ischemic encephalopathy: A randomized controlled trial.
37 *Pediatrics*. 2015; 136(5):e1302-e1309
- 38 126. Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V et al.
39 Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children
40 6-59 months of age: a phase 3, randomized, noninferiority study. *Vaccine*. 2019;
41 37(2):343-351
- 42 127. Stauffer VL, Baygani SK, Kinon BJ, Krikke-Workel JO. A short-term, multicenter,
43 placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3
44 receptor agonist using an electronic patient-reported outcome device in patients with
45 schizophrenia. *Journal of Clinical Psychopharmacology*. 2014; 34(5):552-558

- 1 128. Stefan H, Wang-Tilz Y, Pauli E, Denhofer S, Genow A, Kerling F et al. Onset of
2 action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis
3 (TISA). *Epilepsia*. 2006; 47(3):516-522
- 4 129. Stefan H, Wang Y, Kerling F, Hopp P, Zhou D, Dienel A et al. Therapeutic intensive
5 seizure analysis (TISA) in presurgical evaluation of Losigamone. *Acta Neurologica
6 Scandinavica*. 2001; 104(4):195-201
- 7 130. Strengell T, Uhari M, Tarkka R, Uusimaa J, Alen R, Lautala P et al. Antipyretic agents
8 for preventing recurrences of febrile seizures: randomized controlled trial. *Archives of
9 Pediatrics and Adolescent Medicine*. 2009; 163(9):799-804
- 10 131. Struys MMRF, Valk BI, Eleveld DJ, Absalom AR, Meyer P, Meier S et al. A phase 1,
11 single-center, double-blind, placebo-controlled study in healthy subjects to assess the
12 safety, tolerability, clinical effects, and pharmacokinetics-pharmacodynamics of
13 intravenous cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a single
14 ascending bolus dose. *Anesthesiology*. 2017; 127(1):20-35
- 15 132. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al. Cilengitide combined
16 with standard treatment for patients with newly diagnosed glioblastoma with
17 methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre,
18 randomised, open-label, phase 3 trial. *Lancet Oncology*. 2014; 15(10):1100-1108
- 19 133. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al.
20 Effects of radiotherapy with concomitant and adjuvant temozolomide versus
21 radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year
22 analysis of the EORTC-NCIC trial. *Lancet Oncology*. 2009; 10(5):459-466
- 23 134. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B et al. Effect of
24 tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide
25 alone on survival in patients with glioblastoma a randomized clinical trial. *JAMA -
26 Journal of the American Medical Association*. 2017; 318(23):2306-2316
- 27 135. Sundqvist A, Nilsson BY, Tomson T. Valproate monotherapy in juvenile myoclonic
28 epilepsy: dose-related effects on electroencephalographic and other neurophysiologic
29 tests. *Therapeutic Drug Monitoring*. 1999; 21(1):91-96
- 30 136. Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS.
31 Neuropsychological effects of tiagabine, a potential new antiepileptic drug. *Seizure*.
32 1994; 3(1):29-35
- 33 137. Szaflarski JP, Sadek A, Greve B, Williams P, Varner JA, Moseley BD. Randomized
34 open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of
35 increased seizure activity. *Epilepsy & Behavior*. 2020; 109:107127
- 36 138. Szer J, Durrant S, Schwarzer AP, Bradstock KF, Gibson J, Arthur C et al. Oral versus
37 intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after
38 allogeneic bone marrow transplantation. *Internal Medicine Journal*. 2004; 34(3):98-
39 101
- 40 139. Tacke M, Rupp N, Gerstl L, Heinen F, Vill K, Bonfert M et al. Benign epilepsy with
41 centrotemporal spikes: Correlating spike frequency and neuropsychology. *Acta
42 Neurologica Scandinavica*. 2018; 138(6):475-481
- 43 140. Taghavi Ardakani A, Honarpisheh A, Fakharian E, Talebian A, Jamali M, Moosavi GA
44 et al. Oral versus nasal vasopressin in the treatment of nocturnal enuresis in 5- to 12-
45 year-old children. *Iranian Journal of Child Neurology*. 2010; 4(1):13-16

- 1 141. Taghdiri MM, Ashrafi MR, Bakhshandeh-Bali MK, Taheri-Otaghsara SM, Nasehi MM,
2 Mohammad G. Clinical trial of vigabatrin as adjunctive therapy in children with
3 refractory epilepsy. *Iranian Journal of Pediatrics*. 2013; 23(6):653-658
- 4 142. Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H. Sulfasalazine and
5 temozolomide with radiation therapy for newly diagnosed glioblastoma. *Neurology*
6 *India*. 2014; 62(1):42-47
- 7 143. Tang F, Zhu G, Jiao Z, Ma C, Chen N, Wang B. The effects of medication education
8 and behavioral intervention on Chinese patients with epilepsy. *Epilepsy & Behavior*.
9 2014; 37:157-164
- 10 144. Tartara A, Manni R, Galimberti CA, Morini R, Mumford JP, Iudice A et al. Six-year
11 follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. *Acta*
12 *Neurologica Scandinavica*. 1992; 86(3):247-251
- 13 145. Tatum WO, French JA, Faught E, Morris GL, 3rd, Liporace J, Kanner A et al.
14 Postmarketing experience with topiramate and cognition. *Epilepsia*. 2001;
15 42(9):1134-1140
- 16 146. Temkin NR, Anderson GD, Winn HR, Ellenbogen RG, Britz GW, Schuster J et al.
17 Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised
18 controlled trial. *Lancet Neurology*. 2007; 6(1):29-38
- 19 147. Temkin NR, Dikmen SS, Anderson GD, Wilensky AJ, Holmes MD, Cohen W et al.
20 Valproate therapy for prevention of posttraumatic seizures: a randomized trial.
21 *Journal of Neurosurgery*. 1999; 91(4):593-600
- 22 148. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized,
23 double-blind study of phenytoin for the prevention of post-traumatic seizures. *New*
24 *England Journal of Medicine*. 1990; 323(8):497-502
- 25 149. Tennison M, Greenwood R, Lewis D, Thorn M. Discontinuing antiepileptic drugs in
26 children with epilepsy. A comparison of a six-week and a nine-month taper period.
27 *New England Journal of Medicine*. 1994; 330(20):1407-1410
- 28 150. Terai T, Yukioka H, Fujimori M. A double-blind comparison of lidocaine and
29 mepivacaine during epidural anaesthesia. *Acta Anaesthesiologica Scandinavica*.
30 1993; 37(6):607-610
- 31 151. Thangaratinam S MN, Newton S, Weckesser A, Bagary M, Greenhill L, et al.
32 AntiEpileptic drug monitoring in PREgnancy (EMPiRE): a double-blind randomised
33 trial on effectiveness and acceptability of monitoring strategies. *Health Technology*
34 *Assessment*. 2018; 22(23)
- 35 152. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J et al. Long-term efficacy
36 and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's
37 syndrome). *Archives de Pédiatrie*. 2002; 9(11):1120-1127
- 38 153. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with
39 sodium valproate: randomized, double-blind study. *Indian Pediatrics*. 1996;
40 33(7):549-555
- 41 154. Thilothammal N, Kannan n, Krishnamurthy PV, Kamala KG, Ahamed S, Banu K. Role
42 of phenobarbitone in preventing recurrence of febrile convulsions. *Indian Pediatrics*.
43 1993; 30(5):637-642
- 44 155. Thomas SV, Kurup JR, Kuruvilla A, Nair BN, Thomas KL, Sarma PS. An expert
45 system for the diagnosis of epilepsy: results of a clinical trial. *National Medical*
46 *Journal of India*. 2001; 14(5):274-276

- 1 156. Tilz C, Stefan H, Hopfengaertner R, Kerling F, Genow A, Wang-Tilz Y. Influence of
2 levetiracetam on ictal and postictal EEG in patients with partial seizures. *European*
3 *Journal of Neurology*. 2006; 13(12):1352-1358
- 4 157. Titre-Johnson S, Schoeler N, Eltze C, Williams R, Vezyroglou K, McCullagh H et al.
5 Ketogenic diet in the treatment of epilepsy in children under the age of 2 years: study
6 protocol for a randomised controlled trial. *Trials*. 2017; 18:195
- 7 158. Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M, Wesche D et al. Bioequivalence of
8 oral and intravenous carbamazepine formulations in adult patients with epilepsy.
9 *Epilepsia*. 2015; 56(6):915-923
- 10 159. Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal-related adverse events
11 from clinical trials of clobazam in Lennox-Gastaut syndrome. *Epilepsy & Behavior*.
12 2014; 37:11-15
- 13 160. Tolchin B, Baslet G, Suzuki J, Martino S, Blumenfeld H, Hirsch LJ et al. Randomized
14 controlled trial of motivational interviewing for psychogenic nonepileptic seizures.
15 *Epilepsia*. 2019; 60(5):986-995
- 16 161. Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA. Lamotrigine
17 adjunctive therapy among children and adolescents with primary generalized tonic-
18 clonic seizures. *Pediatrics*. 2006; 118(2):e371-378
- 19 162. Trinkka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Loffler K et al. Efficacy
20 and safety of eslicarbazepine acetate versus controlled-release carbamazepine
21 monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized,
22 parallel-group, multicenter study. *Epilepsia*. 2018; 59(2):479-491
- 23 163. Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J. Gabapentin in
24 naive childhood absence epilepsy: results from two double-blind, placebo-controlled,
25 multicenter studies. *Journal of Child Neurology*. 1996; 11(6):470-475
- 26 164. Tsounis S, Kimiskidis VK, Kazis D, Gkiatas K, Garganis K, Karageorgiou K et al. An
27 open-label, add-on study of pregabalin in patients with partial seizures: a multicenter
28 trial in Greece. *Seizure*. 2011; 20(9):701-705
- 29 165. Tungmanowutthikul S, Champawong R, Songthamwat S, Songthamwat M.
30 Comparison of magnesium sulphate protocols by weight-adjusted versus two grams
31 per hour for preventing convulsion in preeclampsia: A randomised controlled trial.
32 *Journal of Clinical and Diagnostic Research*. 2019; 13(2):QC01-QC04
- 33 166. Turan Gurhopur FD, Isler Dalgic A. The effect of a modular education program for
34 children with epilepsy and their parents on disease management. *Epilepsy &*
35 *Behavior*. 2018; 78:210-218
- 36 167. Uijl SG, Uiterwaal CS, Aldenkamp AP, Carpay JA, Doelman JC, Keizer K et al.
37 Adjustment of treatment increases quality of life in patients with epilepsy: a
38 randomized controlled pragmatic trial. *European Journal of Neurology*. 2009;
39 16(11):1173-1177
- 40 168. Vaghadia H, Chan V, Ganapathy S, Lui A, McKenna J, Zimmer K. A multicentre trial
41 of ropivacaine 7.5 mg x ml(-1) vs bupivacaine 5 mg x ml(-1) for supra clavicular
42 brachial plexus anesthesia. *Canadian Journal of Anaesthesia*. 1999; 46(10):946-951
- 43 169. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP et al. Sequential-design,
44 multicenter, randomized, controlled trial of early decompressive craniectomy in
45 malignant middle cerebral artery infarction (DECIMAL Trial). *Stroke*. 2007;
46 38(9):2506-2517

- 1 170. Van Der Meyden CH, Kruger AJ, Muller FO, Rabie W, Schall R. Acute oral loading of
2 carbamazepine-CR and phenytoin in a double-blind randomized study of patients at
3 risk of seizures. *Epilepsia*. 1994; 35(1):189-194
- 4 171. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and
5 tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset
6 seizures: a phase IIb, randomized, controlled trial. *Epilepsia*. 2013; 54(1):89-97
- 7 172. van Stuijvenberg M, Derksen-Lubsen G, Steyerberg EW, Habbema JD, Moll HA.
8 Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses
9 to prevent febrile seizure recurrences. *Pediatrics*. 1998; 102(5):E51
- 10 173. VanLandingham KE, Crockett J, Taylor L, Morrison G. A phase 2, double-blind,
11 placebo-controlled trial to investigate potential drug-drug interactions between
12 cannabidiol and clobazam. *Journal of Clinical Pharmacology*. 2020; 60(10):1304-
13 1313
- 14 174. Vining EP, Mellitis ED, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP et al.
15 Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind
16 comparison between phenobarbital and valproic acid. *Pediatrics*. 1987; 80(2):165-174
- 17 175. Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL. The safety of liposome
18 bupivacaine, a novel local analgesic formulation. *Clinical Journal of Pain*. 2014;
19 30(2):102-110
- 20 176. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL et al.
21 Adjuvant chemotherapy with or without bevacizumab in patients with resected non-
22 small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
23 *Lancet Oncology*. 2017; 18(12):1610-1623
- 24 177. Wang X, Yang D, Wang S, Zhao X, Zhang L, Chen Z et al. Effects of low-frequency
25 repetitive transcranial magnetic stimulation on electroencephalogram and seizure
26 frequency in 15 patients with temporal lobe epilepsy following dipole source
27 localization. *Neural Regeneration Research*. 2008; 3(11):1257-1260
- 28 178. Wanigasinghe J, Arambepola C, Ranganathan SS, Sumanasena S. Randomized,
29 single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular
30 corticotropin: A 12-month assessment of spasm control in west syndrome. *Pediatric
31 Neurology*. 2017; 76:14-19
- 32 179. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical
33 trial: The long-term safety and tolerability of naloxegol in patients with pain and
34 opioid-induced constipation. *Alimentary Pharmacology and Therapeutics*. 2014;
35 40(7):771-779
- 36 180. Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B et al. Efficacy and safety
37 of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients
38 hospitalized for acute schizophrenia transitioned to outpatient care: Phase 3,
39 randomized, double-blind, active-control ALPINE study. *Journal of Clinical Psychiatry*.
40 2020; 81(3):19m13207
- 41 181. Weinbroum A, Rudick V, Sorkine P, Nevo Y, Halpern P, Geller E et al. Use of
42 flumazenil in the treatment of drug overdose: a double-blind and open clinical study in
43 110 patients. *Critical Care Medicine*. 1996; 24(2):199-206
- 44 182. Welch RD, Nicholas K, Durkalski-Mauldin VL, Lowenstein DH, Conwit R, Mahajan PV
45 et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital
46 treatment of status epilepticus in the pediatric population. *Epilepsia*. 2015; 56(2):254-
47 262

- 1 183. Wheless JW, Meng TC, Van Ess PJ, Detyniecki K, Sequeira DJ, Pullman WE. Safety
2 and efficacy of midazolam nasal spray in the outpatient treatment of patients with
3 seizure clusters: An open-label extension trial. *Epilepsia*. 2019; 60(9):1809-1819
- 4 184. Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin,
5 carbamazepine, and valproic acid on caffeine metabolism. *European Journal of*
6 *Clinical Pharmacology*. 1989; 36(4):401-406
- 7 185. Wijnen BFM, de Kinderen RJA, Lambrechts D, Postulart D, Aldenkamp AP, Majoie M
8 et al. Long-term clinical outcomes and economic evaluation of the ketogenic diet
9 versus care as usual in children and adolescents with intractable epilepsy. *Epilepsy*
10 *Research*. 2017; 132:91-99
- 11 186. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D et al. Axitinib plus
12 pembrolizumab in patients with advanced sarcomas including alveolar soft-part
13 sarcoma: a single-centre, single-arm, phase 2 trial. *Lancet Oncology*. 2019;
14 20(6):837-848
- 15 187. Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D et al. Multicenter double-blind,
16 randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese
17 patients with refractory partial-onset seizures. *Epilepsia*. 2009; 50(3):398-405
- 18 188. Xu F, Feng QH, Yu L, Liu J, Sun HB. Effects of topiramate versus other antiepileptic
19 drugs on the cognitive function of patients with epilepsy. *Neural Regeneration*
20 *Research*. 2007; 2(2):95-98
- 21 189. Xu NG, Zhu DT, Xiao B, Xie GJ. Impact of traditional antiepileptic and topiramate on
22 the quality of life of adult epileptic patients. *Chinese Journal of Clinical Rehabilitation*.
23 2004; 8(25):5386-5388
- 24 190. Yadegary MA, Maemodan FG, Nayeri ND, Ghanjekhanlo A. The effect of self-
25 management training on health-related quality of life in patients with epilepsy.
26 *Epilepsy & Behavior*. 2015; 50:108-112
- 27 191. Yamamoto T, Kubota Y, Murayama H, Ozeki H, Numachi Y, Ikeda A. Appropriate
28 conversion from valproate monotherapy to lamotrigine monotherapy in Japanese
29 women with epilepsy. *Epilepsy and seizure*. 2016; 8(1):21-31
- 30 192. Yamamoto T, Lim SC, Ninomiya H, Kubota Y, Shin WC, Kim DW et al. Efficacy and
31 safety of perampanel monotherapy in patients with focal-onset seizures with newly
32 diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-
33 label Study 342 (FREEDOM Study). *Epilepsia Open*. 2020; 5(2):274-284
- 34 193. Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, Su MS. A double-blind, placebo-controlled
35 study of topiramate in adult patients with refractory partial epilepsy. *Epilepsia*. 2000;
36 41(9):1162-1166
- 37 194. Young AH, Geddes JR, Macritchie K, Rao SN, Vasudev A. Tiagabine in the
38 maintenance treatment of bipolar disorders. *Cochrane Database of Systematic*
39 *Reviews* 2006, Issue 3. Art. No.: CD005173. DOI:
40 10.1002/14651858.CD005173.pub2.
- 41 195. Young KD, Okada PJ, Sokolove PE, Palchak MJ, Panacek EA, Baren JM et al. A
42 randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of
43 early posttraumatic seizures in children with moderate to severe blunt head injury.
44 *Annals of Emergency Medicine*. 2004; 43(4):435-446
- 45 196. Younus SM, Basar S, Gauri SA, Khan AA, Imran M, Abubakar S et al. Comparison of
46 phenytoin versus levetiracetam in early seizure prophylaxis after traumatic brain

- 1 injury, at a tertiary care hospital in Karachi, Pakistan. *Asian Journal of Neurosurgery*.
2 2018; 13(4):1096-1100
- 3 197. Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs
4 carbamazepine in newly diagnosed partial seizures in children. *Archives of*
5 *Neurology*. 1999; 56(5):605-607
- 6 198. Zhang PQ, Liu H, Li HJ. Influence of carbamazepine-phenobarbital combined
7 treatment on IL-1beta, IL-6, Bcl-2 and Bax expression in children with epilepsy.
8 *Biomedical Research (India)*. 2017; 28(19):8501-8504
- 9 199. Zhao J, Sang Y, Zhang Y, Zhang D, Chen J, Liu X. Efficacy of levetiracetam
10 combined with sodium valproate on pediatric epilepsy and its effect on serum miR-
11 106b in children. *Experimental and Therapeutic Medicine*. 2019; 18(6):4436-4442
- 12 200. Zhong WZ, Xu ST, Yan HH, Yang XN, Zhou Q, Wu YL et al. Gefitinib versus
13 vinorelbine plus cisplatin as adjuvant treatment for stage II-III A (N1-N2) EGFR-mutant
14 NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. *Lancet*
15 *Oncology*. 2018; 19(1):139-148
- 16 201. Zhou H, Wang N, Xu L, Huang HL, Yu CY. Clinical study on anti-epileptic drug with B
17 vitamins for the treatment of epilepsy after stroke. *European Review for Medical and*
18 *Pharmacological Sciences*. 2017; 21(14):3327-3331
- 19 202. Zou LP, Wang X, Dong CH, Chen CH, Zhao W, Zhao RY. Three-week combination
20 treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile
21 spasms: a 24-week, randomized, open-label, follow-up study in China. *Clinical*
22 *Therapeutics*. 2010; 32(4):692-700
- 23

Appendices

Appendix A Review protocols

A.1 Review protocol for therapeutic drug monitoring in pregnancy

ID	Field	Content
1.	Review title	What is the appropriate serial monitoring of drug levels, including timing, in girls or women who are thinking about conceiving, are pregnant or in the post-partum period?
2.	Review question	To evaluate whether therapeutic drug monitoring of girls or women on AEDs during pregnancy and post-partum reduces seizure deterioration compared with clinical features monitoring after a reduction in serum AED levels and at which time intervals should monitoring take place.
3.	Objective	The review will determine whether therapeutic drug monitoring of girls and women during and after pregnancy reduces the probability of seizure deterioration and whether particular frequencies of monitoring should be recommended.
4.	Searches	<p>Key paper: EMPIRE study</p> <p>Thangaratinam S, Marlin N, Newton S, Weckesser A, Bagary M, Greenhill L, et al. AntiEpileptic drug Monitoring in PREgnancy (EMPIRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018;22(23):1–152. PMID:29737274</p> <p>The following databases will be searched: Cochrane Central Register of Controlled Trials (CENTRAL)</p> <ul style="list-style-type: none">• Cochrane Database of Systematic Reviews (CDSR)• Embase

		<ul style="list-style-type: none"> • MEDLINE <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language studies • Human studies <p>Other searches:</p> <ul style="list-style-type: none"> • Reference checking of systematic reviews <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p>
5.	Condition or domain being studied	Pregnancy can affect how drugs are metabolised. In women or girls who are pregnant. Drug monitoring can help to assess what effect pregnancy may have on AEDs and what changes to prescribing AEDs might be needed to control seizures.
6.	Population	<p>Inclusion: girls and women planning pregnancy, during pregnancy and postpartum up to 6 months</p> <p>Exclusion: men, non-pregnant women not planning pregnancy</p>
7.	Intervention/Exposure/Test	<p>Drug monitoring (measurement of drug concentration in blood or saliva) of the following AEDs:</p> <p>Brivaracetam</p> <p>Carbamazepine (for focal motor status)</p> <p>Chlormethiazole (clomethiazole)</p> <p>Clobazam</p>

		<p>Clonazepam (for myoclonic status) Diazepam Eslicarbazepine Ethosuximide Fosphenytoin Gabapentin Lacosamide Lamotrigine Levetiracetam Lorazepam Midazolam Oxcarbazepine Perampanel Phenobarbital (phenobarbitone) Phenytoin Pregabalin Primidone Rufinamide Steroids (methylprednisolone, prednisolone) Stiripentol Sulthiame Tiagabine Topiramate Valproate (sodium valproate/ valproic acid) Zonisamide</p> <p>Dose according to prescriber discretion and / or local protocols</p>
8.	Comparator/Reference standard/Confounding factors	usual care (adjustments without level)

9.	Types of study to be included	<p>RCTs</p> <p>Systematic reviews of RCTs</p> <p>Published NMAs and IPDs will be considered for inclusion</p> <p>If insufficient RCT evidence is available, prospective observational comparative studies will be considered only if they adjust for key confounders of age of epilepsy onset, classification (focal, generalised or epilepsy syndrome).</p>
10.	Other exclusion criteria	<p>Non-English language studies.</p> <p>Conference abstracts will be excluded as it is expected there will be sufficient full text published studies available.</p>
11.	Context	<p>During pregnancy, women with epilepsy who take antiepileptic drugs may experience a reduction in serum AED levels. This has the potential to worsen seizure control with potential consequences for the mother and her unborn child. If AED doses are increased in pregnancy this may have consequences on fetal exposure to antiepileptic drugs.</p>
12.	Primary outcomes (critical outcomes)	<ul style="list-style-type: none"> • Mortality of mother or baby at study follow-up • seizure freedom during pregnancy and at 6 months post-partum • Reduction in seizure frequency (50% or greater reduction in seizure frequency) • time to first seizure in pregnancy and up to up to 6 weeks post-partum • time to subsequent seizure up to 1 year • AED drug exposure (mean daily) • quality of life (any validated measures) at study follow-up • adverse events <ul style="list-style-type: none"> – AED related (toxicity)

		<ul style="list-style-type: none"> - Pregnancy complications in mother and baby (admission to HDU/ICU for mother, admission to NICU for baby) - Seizures during labour - Attendance at ED - Congenital anomalies (neural tube defects (spina bifida), limb defects (club foot), cleft lip and palette etc) - Neurodevelopmental outcomes (Griffith Mental Development Scales and the Bayley Scales of Infant and Toddler Development scale)
13.	Secondary outcomes (important outcomes)	None
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>EviBASE will be used for data extraction.</p>
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p>For Intervention reviews</p> <ul style="list-style-type: none"> • Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS) • Randomised Controlled Trial: Cochrane RoB (2.0) • Nonrandomised study, including cohort studies: Cochrane ROBINS-I <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> • papers were included /excluded appropriately • a sample of the data extractions

		<ul style="list-style-type: none"> • correct methods are used to synthesise data • a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
16.	Strategy for data synthesis	<ul style="list-style-type: none"> • Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). • GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome. <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group http://www.gradeworkinggroup.org/</p> <ul style="list-style-type: none"> • Where meta-analysis is not possible, data will be presented, and quality assessed individually per outcome. <p>Heterogeneity between the studies in effect measures will be assessed using the I² statistic and visually inspected. An I² value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random effects.</p> <p>Consider groups identified in the equality impact assessment.</p> <p>Indicate any modifiers of treatment effect/confounders that will be used to try to explain heterogeneity.]</p> <p>Please see example protocols for relevant text:</p> <p>N:\TECHNICAL TEAMS\Research Fellows\Methodology RF\Current processes\Processes same in all types of review\Protocols\Example protocols</p>

17.	Analysis of sub-groups	<p>Groups to be considered from the equality impact assessment: women with learning disabilities</p> <p>Statistically heterogeneity will be assessed by visually examining the forest plots and by calculating the I² inconsistency statistic (with an I² value of more than 50% indicating considerable heterogeneity). In the event of heterogeneity, subgroup analysis will be undertaken based on the following possible modifiers of treatment effect:</p>			
18.	Type and method of review	<input checked="" type="checkbox"/>	Intervention		
		<input type="checkbox"/>	Diagnostic		
		<input type="checkbox"/>	Prognostic		
		<input type="checkbox"/>	Qualitative		
		<input type="checkbox"/>	Epidemiologic		
		<input type="checkbox"/>	Service Delivery		
		<input type="checkbox"/>	Other (please specify)		
19.	Language	English			
20.	Country	England			
23.	Stage of review at time of this submission	Review stage		Started	Completed
		Preliminary searches		<input type="checkbox"/>	<input type="checkbox"/>
		Piloting of the study selection process		<input type="checkbox"/>	<input type="checkbox"/>
		Formal screening of search results against eligibility criteria		<input type="checkbox"/>	<input type="checkbox"/>

		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>
		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
24.	Named contact	<p>5a. Named contact. Angela Cooper National Guideline Centre Angela.cooper@rcplondon.ac.uk</p> <p>5b Named contact e-mail epilepsies@nice.org.uk</p> <p>5b Named contact e-mail epilepsies@nice.org.uk</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>		
25.	Review team members	<p>From the National Guideline Centre: From the National Guideline Centre: Gill Ritchie, Guideline Lead Angela Cooper, Senior Research Fellow Rafina Yarde, Systematic reviewer Margaret Constanti, Senior Health economist Joseph Runicles, Information specialist</p>		
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.		

27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.	
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10112 .	
29.	Other registration details		
30.	Reference/URL for published protocol		
31.	Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE. 	
32.	Keywords		
33.	Details of existing review of same topic by same authors		
34.	Current review status	<input type="checkbox"/>	Ongoing
		<input checked="" type="checkbox"/>	Completed but not published

		<input type="checkbox"/>	Completed and published
		<input type="checkbox"/>	Completed, published and being updated
		<input type="checkbox"/>	Discontinued
35.	Additional information		
36.	Details of final publication	www.nice.org.uk	

1 A.2 Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2004, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Studies published after 2004 that were included in the previous guideline(s) will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).²⁵</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with “Minor limitations” then it will be included in the guideline. A health economic evidence table will be completed, and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with “Very serious limitations” then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed, and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p> <p>The health economist will be guided by the following hierarchies.</p>

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2004 or later (including any such studies included in the previous guideline(s)) but that depend on unit costs and resource data entirely or predominantly from before 2004 will be rated as 'Not applicable'.
- Studies published before 2004 (including any such studies included in the previous guideline(s)) will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B Literature search strategies

This literature search strategy was used for the following review:

- To evaluate whether therapeutic drug monitoring of girls or women on AEDs during pregnancy and post-partum reduces seizure deterioration compared with clinical features monitoring after a reduction in serum AED levels and at which time intervals should monitoring take place.

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.²⁵

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Table 5: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 10 August 2020	Randomised controlled trials Systematic review studies Observational studies Exclusions
Embase (OVID)	1974 – 10 August 2020	Randomised controlled trials Systematic review studies Observational studies Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 8 of 12 CENTRAL to 2020 Issue 8 of 12	None

Medline (Ovid) search terms

1.	exp female/
2.	exp pregnancy/
3.	pregnancy outcome/
4.	exp pregnancy complications/
5.	exp prenatal exposure delayed effects/
6.	postnatal care/
7.	postpartum period/
8.	exp Breast Feeding/
9.	(female* or wom?n or girl or pregnan* or conception or prenatal or pre-natal or postnatal or post-natal or postpartum or post-partum or conceiv* or breast feed* or breastfeed* or breastfed or breast fed or breast milk or breastmilk or mother* milk or human milk or colostrum).ti,ab.

10.	or/1-9
11.	exp epilepsy/
12.	seizures/
13.	exp status epilepticus/
14.	seizures, febrile/
15.	(dravet syndrome or epilep* or convuls* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome).ti,ab.
16.	or/11-15
17.	10 and 16
18.	letter/
19.	editorial/
20.	news/
21.	exp historical article/
22.	Anecdotes as Topic/
23.	comment/
24.	case report/
25.	(letter or comment*).ti.
26.	or/18-25
27.	randomized controlled trial/ or random*.ti,ab.
28.	26 not 27
29.	animals/ not humans/
30.	exp Animals, Laboratory/
31.	exp Animal Experimentation/
32.	exp Models, Animal/
33.	exp Rodentia/
34.	(rat or rats or mouse or mice).ti.
35.	or/28-34
36.	17 not 35
37.	randomized controlled trial.pt.
38.	controlled clinical trial.pt.
39.	randomi#ed.ti,ab.
40.	placebo.ab.
41.	randomly.ti,ab.
42.	Clinical Trials as topic.sh.
43.	trial.ti.
44.	or/37-43
45.	Meta-Analysis/
46.	exp Meta-Analysis as Topic/
47.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
48.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
49.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
50.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
51.	(search* adj4 literature).ab.
52.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.

53.	cochrane.jw.
54.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
55.	or/45-54
56.	Epidemiologic studies/
57.	Observational study/
58.	exp Cohort studies/
59.	(cohort adj (study or studies or analys* or data)).ti,ab.
60.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
61.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
62.	Controlled Before-After Studies/
63.	Historically Controlled Study/
64.	Interrupted Time Series Analysis/
65.	(before adj2 after adj2 (study or studies or data)).ti,ab.
66.	exp case control studies/
67.	case control*.ti,ab.
68.	Cross-sectional studies/
69.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
70.	or/56-69
71.	Monitoring, Physiologic/ or Monitoring, Ambulatory/ or Neurophysiological Monitoring/
72.	monitor*.ti,ab.
73.	Patient compliance/ or Medication Adherence/ or Drug Monitoring/
74.	exp Patient Outcome Assessment/
75.	("patient reported outcome measures" or PROM).ti,ab.
76.	"Continuity of Patient Care"/
77.	patient care/
78.	"Delivery of Health Care, Integrated"/
79.	critical pathways/
80.	((care or clinical or critical or patient*) adj2 manag*).ti,ab.
81.	Telemetry/ or Telemedicine/
82.	(telemonitor* or telemedicine or telehealth or tele medicine or tele health or smartphone* or smart phone or ipad* or iphone* or device* or virtual or remote or wireless or internet or wifi or wi fi).ti,ab.
83.	exp "Appointments and Schedules"/
84.	Self-Care/
85.	(self adj (care or caring or manag* or checkup or check* up or assess* or test* or evaluat*).ti,ab.
86.	((survellian* or review* or assess* or test* or evaluat* or program* or observed or observation* or provision or strateg* or clinic or clinics or pattern* or followup* or follow up* or checkup or check up* or appointment*) adj3 (timing* or timed or time point* or times or duration or interval* or year* or annual* or biannual or month* or period* or frequen* or infrequent* or continu* or intermittent or irregular or routine* or regular* or schedul* or longterm or long term or short-term or short term or early or earliest * or proactiv* or special* or nurse* or general practi* or GP or family practi* or doctor* or medical or physician* or patient* or outpatient* or out-patient*).ti,ab.
87.	((drug* or medication* or pharm*) adj (compliance or complying or adher*).ti,ab.
88.	or/71-87
89.	36 and 88
90.	89 and (44 or 55 or 70)

91.	limit 90 to English language
-----	------------------------------

1

Embase (Ovid) search terms

1.	exp female/
2.	exp pregnancy/
3.	pregnancy outcome/
4.	pregnancy complication/
5.	prenatal exposure/
6.	postnatal care/
7.	puerperium/
8.	breast feeding/
9.	(female* or wom?n or girl or pregnan* or conception or prenatal or pre natal or postnatal or post natal or postpartum or post-partum or conceiv* or breast feed* or breastfeed* or breastfed or breast fed or breast milk or breastmilk or mother* milk or human milk or colostrum).ti,ab.
10.	or/1-9
11.	exp epilepsy/
12.	seizure/
13.	epileptic state/
14.	febrile convulsion/
15.	(dravet syndrome or epilep* or convuls* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome).ti,ab.
16.	or/11-15
17.	letter.pt. or letter/
18.	note.pt.
19.	editorial.pt.
20.	case report/ or case study/
21.	(letter or comment*).ti.
22.	or/17-21
23.	randomized controlled trial/ or random*.ti,ab.
24.	22 not 23
25.	animal/ not human/
26.	nonhuman/
27.	exp Animal Experiment/
28.	exp Experimental Animal/
29.	animal model/
30.	exp Rodent/
31.	(rat or rats or mouse or mice).ti.
32.	or/24-31
33.	*physiologic monitoring/
34.	*ambulatory monitoring/
35.	*neurophysiological monitoring/
36.	monitor*.ti,ab.
37.	*patient compliance/
38.	*medication compliance/
39.	*drug monitoring/
40.	*outcome assessment/
41.	("patient reported outcome measures" or PROM).ti,ab.

42.	*patient care/
43.	*integrated health care system/
44.	*clinical pathway/
45.	((care or clinical or critical or patient*) adj2 manag*).ti,ab.
46.	*telemetry/
47.	*telemedicine/
48.	(telemonitor* or telemedicine or telehealth or tele medicine or tele health or smartphone* or smart phone or ipad* or iphone* or device* or virtual or remote or wireless or internet or wifi or wi fi).ti,ab.
49.	*hospital management/
50.	*self care/
51.	(self adj (care or caring or manag* or checkup or check* up or assess* or test* or evaluat*)).ti,ab.
52.	((surveillan* or review* or assess* or test* or evaluat* or program* or observed or observation* or provision or strateg* or clinic or clinics or pattern* or followup* or follow up* or checkup or check up* or appointment*) adj3 (timing* or timed or time point* or times or duration or interval* or year* or annual* or biannual* or month* or period* or frequen* or infrequent* or continu* or intermittent or irregular or routine* or regular* or schedul* or longterm or long term or short-term or short term or early or earliest * or proactiv* or special* or nurse* or general practi* or GP or family practi* or doctor* or medical or physician* or patient* or outpatient* or out-patient*)).ti,ab.
53.	((drug* or medication* or pharm*) adj (compliance or complying or adher*)).ti,ab.
54.	or/33-53
55.	random*.ti,ab.
56.	factorial*.ti,ab.
57.	(crossover* or cross over*).ti,ab.
58.	((doubl* or singl*) adj blind*).ti,ab.
59.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
60.	crossover procedure/
61.	single blind procedure/
62.	randomized controlled trial/
63.	double blind procedure/
64.	or/55-63
65.	systematic review/
66.	meta-analysis/
67.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
68.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
69.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
70.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
71.	(search* adj4 literature).ab.
72.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
73.	cochrane.jw.
74.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
75.	or/65-74
76.	Clinical study/
77.	Observational study/
78.	family study/

79.	longitudinal study/
80.	retrospective study/
81.	prospective study/
82.	cohort analysis/
83.	follow-up/
84.	cohort*.ti,ab.
85.	83 and 84
86.	(cohort adj (study or studies or analys* or data)).ti,ab.
87.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
88.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
89.	(before adj2 after adj2 (study or studies or data)).ti,ab.
90.	exp case control study/
91.	case control*.ti,ab.
92.	cross-sectional study/
93.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
94.	or/76-82,85-93
95.	10 and 16
96.	95 not 32
97.	54 and 96
98.	97 and (64 or 75 or 94)
99.	limit 98 to English language

1

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Female] explode all trees
#2.	MeSH descriptor: [Pregnancy] explode all trees
#3.	MeSH descriptor: [Pregnancy Outcome] explode all trees
#4.	MeSH descriptor: [Pregnancy Complications] explode all trees
#5.	MeSH descriptor: [Prenatal Exposure Delayed Effects] explode all trees
#6.	MeSH descriptor: [Postnatal Care] explode all trees
#7.	MeSH descriptor: [Postpartum Period] explode all trees
#8.	MeSH descriptor: [Breast Feeding] explode all trees
#9.	(female* or wom?n or girl or pregnan* or conception or prenatal or pre natal or postnatal or post natal or postpartum or post partum or conceiv* or breast feed* or breastfeed* or breastfed or breast fed or breast milk or breastmilk or mother* milk or human milk or colostrum):ti,ab
#10.	(or #1-#9)
#11.	MeSH descriptor: [Epilepsy] explode all trees
#12.	MeSH descriptor: [Seizures] this term only
#13.	MeSH descriptor: [Status Epilepticus] explode all trees
#14.	MeSH descriptor: [Seizures, Febrile] this term only
#15.	(dravet syndrome or epilep* or convuls* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome):ti,ab
#16.	(or #11-#15)
#17.	#10 and #16
#18.	MeSH descriptor: [Monitoring, Physiologic] this term only
#19.	MeSH descriptor: [Monitoring, Ambulatory] this term only

#20.	MeSH descriptor: [Neurophysiological Monitoring] this term only
#21.	monitor*:ti,ab
#22.	MeSH descriptor: [Patient Compliance] this term only
#23.	MeSH descriptor: [Medication Adherence] this term only
#24.	MeSH descriptor: [Drug Monitoring] this term only
#25.	MeSH descriptor: [Patient Outcome Assessment] explode all trees
#26.	("patient reported outcome measures" or PROM):ti,ab
#27.	MeSH descriptor: [Continuity of Patient Care] this term only
#28.	MeSH descriptor: [Patient Care] this term only
#29.	MeSH descriptor: [Delivery of Health Care, Integrated] this term only
#30.	MeSH descriptor: [Critical Pathways] this term only
#31.	((care or clinical or critical or patient*) near/2 manag*):ti,ab
#32.	MeSH descriptor: [Telemetry] this term only
#33.	MeSH descriptor: [Telemedicine] this term only
#34.	(telemonitor* or telemedicine or telehealth or tele medicine or tele health or smartphone* or smart phone or ipad* or iphone* or device* or virtual or remote or wireless or internet or wifi or wi fi):ti,ab
#35.	MeSH descriptor: [Appointments and Schedules] explode all trees
#36.	MeSH descriptor: [Self Care] this term only
#37.	(self near (care or caring or manag* or checkup or check* up or assess* or test* or evaluat*)):ti,ab
#38.	((survellian* or review* or assess* or test* or evaluat* or program* or observed or observation* or provision or strateg* or clinic or clinics or pattern* or followup* or follow up* or checkup or check up* or appointment*) near/3 (timing* or timed or time point* or times or duration or interval* or year* or annual* or biannual or month* or period* or frequen* or infrequent* or continu* or intermittent or irregular or routine* or regular* or schedul* or longterm or long term or short-term or short term or early or earliest* or proactiv* or special* or nurse* or general practi* or GP or family practi* or doctor* or medical or physician* or patient* or outpatient* or out-patient*)):ti,ab
#39.	((drug* or medication* or pharm*) near (compliance or complying or adher*)):ti,ab
#40.	(or #18-#39)
#41.	#17 and #40

1 B.2 Health Economics literature search strategy

2 Health economic evidence was identified by conducting a broad search relating to an
3 Epilepsies population in NHS Economic Evaluation Database (NHS EED – this ceased to be
4 updated after March 2015) and the Health Technology Assessment database (HTA) with no
5 date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and
6 Dissemination (CRD). Additional searches were run on Medline and Embase for health
7 economics and quality of life studies.

8 **Table 6: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	Health Economics 1 January 2014 – 13 May 2021	Health economics studies Quality of life studies
	Quality of Life 1946 – 13 May 2021	Exclusions
Embase	Health Economics 1 January 2014 – 13 May 2021	Health economics studies Quality of life studies

Database	Dates searched	Search filter used
	Quality of Life 1974 – 13 May 2021	Exclusions
Centre for Research and Dissemination (CRD)	HTA - Inception – 13 May 2021 NHSEED - Inception to 31 March 2015	None

1

Medline (Ovid) search terms

1.	exp epilepsy/
2.	seizures/
3.	exp status epilepticus/
4.	seizures, febrile/
5.	(dravet syndrome or epilep* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti
24.	or/17-23
25.	6 not 24
26.	limit 25 to English language
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti

38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	quality-adjusted life years/
45.	sickness impact profile/
46.	(quality adj2 (wellbeing or well being)).ti,ab.
47.	sickness impact profile.ti,ab.
48.	disability adjusted life.ti,ab.
49.	(qal* or qtime* or qwb* or daly*).ti,ab.
50.	(euroqol* or eq5d* or eq 5*).ti,ab.
51.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
52.	(hui or hui1 or hui2 or hui3).ti,ab.
53.	(health* year* equivalent* or hye or hyes).ti,ab.
54.	discrete choice*.ti,ab.
55.	rosser.ti,ab.
56.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
57.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
58.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
59.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
60.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
61.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
62.	or/44-61
63.	26 and (43 or 62)

1

Embase (Ovid) search terms

1.	exp *epilepsy/
2.	*landau kleffner syndrome/
3.	exp *seizure/
4.	"seizure, epilepsy and convulsion"/
5.	(dravet syndrome or epilep* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/

17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/15-21
23.	6 not 22
24.	limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.
32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	quality adjusted life year/
40.	sickness impact profile/
41.	(quality adj2 (wellbeing or well being)).ti,ab.
42.	sickness impact profile.ti,ab.
43.	disability adjusted life.ti,ab.
44.	(qal* or qtime* or qwb* or daly*).ti,ab.
45.	(euroqol* or eq5d* or eq 5*).ti,ab.
46.	(qol* or hqj* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
47.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
48.	(hui or hui1 or hui2 or hui3).ti,ab.
49.	(health* year* equivalent* or hye or hyes).ti,ab.
50.	discrete choice*.ti,ab.
51.	rosser.ti,ab.
52.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
53.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
54.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
55.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
56.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
57.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
58.	or/39-57
59.	24 and (38 or 58)

1

NHS EED and HTA (CRD) search terms


#1.	MeSH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#2.	MeSH DESCRIPTOR Seizures EXPLODE ALL TREES

#3.	MeSH DESCRIPTOR Status Epilepticus EXPLODE ALL TREES
#4.	MeSH DESCRIPTOR Seizures, Febrile EXPLODE ALL TREES
#5.	((dravet syndrome or epilep* or continuous spike wave or slow sleep or landau kleffner syndrome or lennox gastaut syndrome or infant* spasm* or seizure* or west syndrome))
#6.	#1 OR #2 OR #3 OR #4 OR #5

1
2
3
4

Appendix C Effectiveness evidence study selection

Figure 1: Flow chart of clinical study selection for the review of therapeutic drug monitoring in pregnancy



Appendix D Effectiveness evidence

Study	THANGARATINAM 2018 trial: Thangaratinam s 2018 ¹⁵¹
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants)	1 (n=263)
Countries and setting	Conducted in United Kingdom; Setting: Obstetric and/or epilepsy clinics in secondary and tertiary care units.
Line of therapy	Not applicable
Duration of study	Intervention + follow up: From antenatal booking until 6 weeks post-partum
Method of assessment of guideline condition	Unclear method of assessment/diagnosis: Inclusion criteria specified a 'confirmed diagnosis of epilepsy including primary, localised or unclassified.'
Stratum	Overall
Subgroup analysis within study	Not applicable: Subgroup analyses were undertaken only to check for effect modification and to assess statistical assumptions.
Inclusion criteria	Viable pregnancy of < 24 weeks' gestation; confirmed diagnosis of epilepsy (including primary, localised or unclassified); lamotrigine monotherapy/polytherapy (with carbamazepine, phenytoin or levetiracetam) or carbamazepine monotherapy or phenytoin monotherapy or levetiracetam monotherapy; capable of understanding the information provided; and ≥25% reduction in serum AED level at any time in pregnancy, compared with baseline or pre-pregnancy levels
Exclusion criteria	Aged < 16 years; documented status epilepticus in the last year or non-epileptic seizures in the last 2 years; non-lamotrigine polytherapy or sodium valproate monotherapy or polytherapy; participation in any blinded, placebo-controlled trials of investigational medicinal products in pregnancy; significant learning disability; unable to complete seizure diaries or recall frequency of seizures accurately; history of alcohol or substance abuse or dependence in the last 2 years; or an expressed intention not to take anti-epileptic drugs in pregnancy.

Recruitment/selection of patients	No details.
Age, gender and ethnicity	Age: Not stated. Gender: All females. Ethnicity: White, Black, Asian, Mixed, Other
Further population details	
Extra comments	.
Indirectness of population	No indirectness: The study population comprised pregnant women with a confirmed diagnosis of epilepsy, during pregnancy and up to 6 weeks post-partum.
Interventions	<p>(n=133) Intervention 1: Usual care. As for the intervention group, participants in the Clinical Features Monitoring (CFM) control group participated in the RCT only if serum AED levels reduced by $\geq 25\%$ compared with pre-pregnancy or initial antenatal visit. A decision to change AED dosage was made without either the clinician or mother having knowledge of monthly serum AED levels, unless an unblinding procedure was requested. The conditions for unblinding were: (i) deterioration of seizures despite treatment (in which case the serum AED level was revealed at the request of the clinician), (ii) clinical suspicion of toxicity, (iii) if levels were above the therapeutic range with risks of toxicity, or (iv) if results were requested by the clinician or mother for any other reason. Duration From randomisation until 6 to 8 weeks post-partum. Concurrent medication/care: Obstetric care. Indirectness: No indirectness; Indirectness comment: Although serum AED levels were measured for the control group, the protocol condition of 'usual care (adjustments without level)' was fulfilled. Comments: 2 women from the original randomised CFM arm (n=135) were randomised in error after the end of pregnancy. They were analysed with a non-randomised group (for which data were not extracted).</p> <p>(n=130) Intervention 2: Monitoring of AEDs - Combination of drugs. As for the control (CFM) group, all women in the intervention (TDM) group participated in the RCT only if serum AED levels reduced by $\geq 25\%$ compared with pre-pregnancy or initial antenatal visit. Monthly serum AED levels were communicated to the responsible clinicians. The clinician discussed with the mother the potential risk of reduced serum levels and the risks and benefits to both mother and baby of increasing the doses. Shared decisions were made on the basis of the following options: (i) more frequent TDM, (ii) immediate dose increase, or (iii) delayed increase pending early testing. Duration From randomisation until 6 to 8 weeks post-partum. Concurrent medication/care: Obstetric care. Indirectness: No indirectness; Indirectness comment: The AEDs monitored were all among those specified in the protocol. Comments: 2 women from the original randomised TDM arm (n=132) were randomised in error after the end of pregnancy. They were analysed with a non-randomised group (for which data were not extracted).</p>

Funding	Academic or government funding (National Institute for Health Research)
RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: THERAPEUTIC DRUG MONITORING versus USUAL CARE	
<p>Protocol outcome 1: Quality of life at As stated</p> <p>- Actual outcome: Maternal quality of life (QOLIE-31) at From randomisation to 36 weeks gestation.; Group 1: mean 71 (SD 16); n=114, Group 2: mean 73.7 (SD 13.5); n=110; QOLIE-31 0 to 100 Top=--; Comments: Adjusted MD (95%CI): -2.5 (-5.1 to 0.0)</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome. Lack of clinician blinding was unlikely to risk performance bias. ; Indirectness of outcome: No indirectness ; Baseline details: N (%) for TDM versus CFM: Maternal congenital abnormalities 5(4) versus 5(4); Diabetes 3(2) versus 1(1); Chronic hypertension 2(2) versus 2(2); Renal disease 3(2) versus 2(2); HIV infection 0(0) versus 0(0); Learning difficulties 3(2) versus 1(1); Mental illness 19(15) versus 15(11). ; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 16; Group 2 Number missing: 23</p> <p>- Actual outcome: Maternal quality of life (QOLIE-31 overall health) at From randomisation to 36 weeks gestation.; Group 1: mean 6.9 (SD 1.8); n=115, Group 2: mean 7.3 (SD 1.6); n=110; QOLIE-31 (overall health) Maximum score 10 Top=High is good outcome; Comments: Adjusted MD (95%CI): -0.35 (-0.72 to 0.02)</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome. Lack of clinician blinding was unlikely to risk performance bias. ; Indirectness of outcome: No indirectness ; Baseline details: N (%) for TDM versus CFM: Maternal congenital abnormalities 5(4) versus 5(4); Diabetes 3(2) versus 1(1); Chronic hypertension 2(2) versus 2(2); Renal disease 3(2) versus 2(2); HIV infection 0(0) versus 0(0); Learning difficulties 3(2) versus 1(1); Mental illness 19(15) versus 15(11). ; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 15; Group 2 Number missing: 23</p> <p>- Actual outcome: Maternal quality of life (EQ-5D) at From randomisation to 6 weeks post-partum.; Group 1: mean 0.9 (SD 0.2); n=99, Group 2: mean 0.9 (SD 0.18); n=102; EQ-5D Maximum score 1 Top=High is good outcome; Comments: Adjusted MD (95%CI): 0.00 (-0.05 to 0.05)</p> <p>Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome. Lack of clinician blinding was unlikely to risk performance bias. ; Indirectness of outcome: No indirectness ; Baseline details: N (%) for TDM versus CFM: Maternal congenital abnormalities 5(4) versus 5(4); Diabetes 3(2) versus 1(1); Chronic hypertension 2(2) versus 2(2); Renal disease 3(2) versus 2(2); HIV infection 0(0) versus 0(0); Learning difficulties 3(2) versus 1(1); Mental illness 19(15) versus 15(11). ; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 31; Group 2 Number missing: 31</p>	

Protocol outcome 2: Seizure freedom during pregnancy and at 6 months post-partum as stated

- Actual outcome: Proportion of women who experienced no seizures. From randomisation to 6 weeks post-partum.; Group 1: 79/127, Group 2: 80/130

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors, self-completing a seizure diary that was designed for the trial. Bias could arise through differential reporting of what is sometimes a subjective outcome. Lack of clinician blinding was unlikely to risk performance bias; Indirectness of outcome: No indirectness, Comments: Period of observation in study (up to 6 weeks post-partum) is shorter than that specified in the review protocol (up to 6 months post-partum) but is still clinically useful.; Baseline details: Age 1st seizure, years since 1st seizure, seizures 3 months prior, seizure class, AED dose at baseline and randomisation and medical history (7 variables). All comparable except complex seizures (TDM 28% v CFM 14%) and mean dose CBZ at rand (TDM 581.3mg v CFM 695mg).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 3; Group 2 Number missing: 3

Protocol outcome 3: Mortality of mother or baby at study follow-up

- Actual outcome: Maternal mortality rate. From randomisation to 6 weeks post-partum.; Group 1: 0/130, Group 2: 0/133

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias; Indirectness of outcome: No indirectness; Baseline details: Smoking status, alcohol intake and medical history (7 variables). All comparable.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0
- Actual outcome: Rate of stillbirth. From randomisation to end of pregnancy.; Group 1: 0/125, Group 2: 2/134; Comments: Unclear why CFM number analysed exceeds number randomised to that group.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Unclear why CFM number analysed exceeds number randomised to that group. Data available for 134 women (133 randomised); Indirectness of outcome: No indirectness; Baseline details: Smoking status, alcohol intake, medical history (7 variables), previous neonatal death or stillbirth, at least 1 previous child with congenital abnormality, AED intake at baseline and randomisation. All comparable except CBZ intake at randomisation.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 5; Group 2 Number missing: 0
- Actual outcome: Neonatal mortality rate. at Not stated.; Group 1: 0/126, Group 2: 0/134; Comments: Unclear why CFM number analysed exceeds number randomised to that group.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -

There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Unclear why CFM number analysed exceeds number randomised to that group. Data available for 134 women (133 randomised); Indirectness of outcome: No indirectness, Comments: The time-period is assumed to be within 28 days of a live birth. • The review protocol stipulates 'mortality of mother or baby at study follow-up.' The study outcome is judged to be consistent with the review protocol stipulation and is judged not to constitute indirectness; Baseline details: Smoking status, alcohol intake, medical history (7 variables), previous neonatal death or stillbirth, at least 1 previous child with congenital abnormality, AED intake at baseline and randomisation. All comparable except CBZ intake at randomisation.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 4; Group 2 Number missing: 0

Protocol outcome 4: Time to first seizure in pregnancy and up to up to 6 weeks post-partum and time to subsequent seizure up to 1 year

- Actual outcome: Time to first seizure. Cumulative analysis time of 25,001 days from randomisation to first seizure; Group 1: n=127; Group 2: n=130; HR 0.82; Lower CI 0.55 to Upper CI 1.2; Test statistic: Cox proportional hazards model; Comments: The authors stated: 'There was a 20% reduction in the time to first seizure with therapeutic drug monitoring compared with clinical features monitoring, a difference that was not significant (HR 0.8, 95% CI 0.55 to 1.2). However, the point estimate HR would correspond to an increase in time (rather than the stated 'reduction in time') to first seizure (TDM versus CFM).

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors, self-completing a seizure diary that was designed for the trial. Bias could arise through differential reporting of what is sometimes a subjective outcome. Lack of clinician blinding was unlikely to risk performance bias; Indirectness of outcome: No indirectness; Baseline details: Covariates: AED type, seizures 3 months prior to consent, mat age (not reported), age at 1st seizure, seizure classification. Additional possible confounders: smoking, alcohol intake, med history (7 variables), AED dose and years since 1st seizure. Comparable except CBZ dose and % with complex seizures.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 3; Group 2 Number missing: 3

- Actual outcome: Overall time to first and subsequent seizures. Cumulative analysis time of 35,859 days from randomisation to censoring; Group 1: n=127 ; Group 2: n=130; HR 1.34; Lower CI 0.7 to Upper CI 2.6; Test statistic: Andersen-Gill modification of Cox proportional hazards model for analysis of events that recur within a single subject.; Comments: The authors stated: 'The analysis of overall time to first seizure and subsequent seizures showed a larger increase with therapeutic drug monitoring than clinical features monitoring, but this was not significant (HR 1.3, 95% CI 0.7 to 2.6). However, the point estimate HR would correspond to a decrease (rather than the reported increase) in time to first and subsequent seizures (TDM versus CFM).

Risk of bias: All domain - Very high, Selection - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors, self-completing a seizure diary that was designed for the trial. Bias could arise through differential reporting of what is sometimes a subjective outcome. Lack of clinician blinding was unlikely to risk performance bias; Indirectness of outcome: No indirectness, Comments: Follow-up time for subsequent seizures (6 weeks) was shorter than specified in the review protocol (1 year) but is still clinically useful.; Baseline details: Covariates: AED type, seizures 3 months prior to consent, mat age (not reported), age at 1st seizure, seizure classification. Additional possible confounders: smoking, alcohol intake, med history (7 variables), AED dose and years since 1st seizure. Comparable except CBZ dose and % with complex seizures.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 3; Group 2 Number missing: 3

Protocol outcome 5: AED exposure as stated

- Actual outcome: Mean daily dose of AED prescribed: CBZ monotherapy. From randomisation to 6 weeks post-partum.; Group 1: mean 616.7 mg (SD 355.8); n=16, Group 2: mean 695 mg (SD 336.4); n=20; Comments: MD (95%CI) for TDM effect: -12.1 (-226.7 to 202.4)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias.; Indirectness of outcome: No indirectness; Baseline details: Possible confounders: alcohol intake (comparable across groups) and other medications used (not reported).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0

- Actual outcome: Mean daily dose of AED prescribed: LTG monotherapy. From randomisation to 6 weeks post-partum.; Group 1: mean 290.9 mg (SD 137.5); n=68, Group 2: mean 252.6 mg (SD 148); n=70; Comments: MD (95%CI) for TDM effect: 32.3 (-14.4 to 79.0)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias.; Indirectness of outcome: No indirectness; Baseline details: Possible confounders: alcohol intake (comparable across groups) and other medications used (not reported).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0

- Actual outcome: Mean daily dose of AED prescribed: LEV monotherapy. From randomisation to 6 weeks post-partum.; Group 1: mean 1735.6 mg (SD 701.9); n=31, Group 2: mean 1628.5 mg (SD 926.5); n=31; Comments: MD(95%CI) for TDM effect: 166.5 (-229.8 to 562.7)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias.; Indirectness of outcome: No indirectness; Baseline details: Possible confounders: alcohol intake (comparable across groups) and other medications used (not reported).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0

- Actual outcome: Mean daily dose of AED prescribed: LTG and LEV polytherapy - LTG component. From randomisation to 6 weeks post-partum.; Group 1: mean 487.5 mg (SD 206.7); n=11, Group 2: mean 413.8 mg (SD 91.1); n=14; Comments: MD (95%CI) for TDM effect: 97.4 (-28.7 to 223.4). NOTE: REPORTED NUMBER ANALYSED IN EACH GROUP MAY HAVE BEEN REVERSED IN ERROR.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Reported number observed in each group for this outcome appears to have been swapped in error. Note that reversed numbers tally in Table 3.; Indirectness of outcome: No indirectness; Baseline details: Possible confounders: alcohol intake (comparable across groups) and other medications used (not reported).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-

randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0

- Actual outcome: Mean daily dose of AED prescribed: LTG and LEV polytherapy - LEV component. From randomisation to 6 weeks post-partum.; Group 1: mean 1920.1 mg (SD 858.9); n=11, Group 2: mean 2122.2 mg (SD 1077.5); n=14; Comments: MD (95%CI) for TDM effect: -137.3 (-945.9 to 671.4). NOTE: REPORTED NUMBER ANALYSED IN EACH GROUP MAY HAVE BEEN REVERSED IN ERROR.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Reported number observed in each group for this outcome appears to have been swapped in error. Note reversed numbers tally with Table 3.; Indirectness of outcome: No indirectness; Baseline details: Possible confounders: alcohol intake (comparable across groups) and other medications used (not reported).; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 0; Group 2 Number missing: 0

Protocol outcome 6: Adverse events as stated

- Actual outcome: Maternal admission to HDU/ICU. From randomisation to 6 weeks post-partum.; Group 1: 5/127, Group 2: 3/130; Comments: OR (95%CI): 1.8 (0.41 to 7.8)

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias.; Indirectness of outcome: No indirectness; Baseline details: Smoking status, alcohol intake and medical history (7 variables). All comparable.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 3; Group 2 Number missing: 3

- Actual outcome: Rate of major congenital malformation. From randomisation to 6 weeks post-partum.; Group 1: 7/125, Group 2: 10/134; Comments: OR (95%CI) 0.66 (0.23 to 1.8)

Unclear why the number analysed in the CFM arm exceeded the number randomised.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments - There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Unclear why CFM number analysed exceeds number randomised to that group. Data available for 134 women (133 randomised); Indirectness of outcome: No indirectness, Comments: Major congenital malformations were defined in the study as 'structural abnormalities with surgical, medical or cosmetic importance diagnosed either antenatally or postnatally.' The review protocol stipulates 'congenital anomalies (neural tube defects (spina bifida), limb defects (club foot), cleft lip and palette etc).'

The study outcome is consistent with the review protocol stipulation and is judged not to constitute indirectness; Baseline details: Smoking status, alcohol intake, previous neonatal death or stillbirth, at least 1 previous child with congenital abnormality, AED intake at baseline and randomisation. All comparable except CBZ intake at randomisation.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 5; Group 2 Number missing: 0

- Actual outcome: Rate of admission to neonatal unit. Time period of observation not stated. Assumed to be from randomisation to 4 weeks post-partum.; Group 1: 16/125, Group 2: 18/134; Comments: OR (95%CI) 1.6 (0.29 to 9.5)

Unclear why the number analysed in the CFM arm exceeded the number randomised.

Risk of bias: All domain - High, Selection - High, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -

There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. Lack of clinician blinding was unlikely to risk performance bias. Unclear why CFM number analysed exceeds number randomised to that group. Data available for 134 women (133 randomised); Indirectness of outcome: No indirectness; Baseline details: Smoking status, alcohol intake, medical history (7 variables), previous neonatal death or stillbirth, at least 1 previous child with congenital abnormality, AED intake at baseline and randomisation. All comparable except CBZ intake at randomisation.; Blinding details: Described as 'double blind' but this refers to clinicians and women in the CFM arm being blind to serum AED levels, and to whether allocated to CFM or non-randomised cohort. CFM decisions were made in knowledge that unblinding was possible.; Group 1 Number missing: 5; Group 2 Number missing: 0


Protocol outcomes not reported by the study

1 **Appendix E Forest plots**

2 **E.1 Therapeutic drug monitoring (TDM) versus clinical features**
3 **monitoring (CFM)**

4

Figure 2: Risk of first seizure



5


Figure 3: Risk of multiple seizures



6

7

Figure 4: Quality of life (QOLIE-31 overall health)




Range of scores 0 to 10; better indicated by higher values.

8

9

Figure 5: Quality of life (QOLIE-31)




Range of scores 0 to 100; better indicated by higher values.

10

11


Figure 6: Quality of life (EQ-5D)



Range of scores 0 to 1; better indicated by higher values.


1
2

Figure 7: Seizure freedom




3
4

Figure 8: Maternal mortality




5
6

Figure 9: Maternal admission to HDU/ICU




7
8

Figure 10: Mean daily carbamazepine exposure (monotherapy)




9
10

Figure 11: Mean daily lamotrigine exposure (monotherapy)




1
2

Figure 12: Mean daily levetiracetam exposure (monotherapy)




3
4

Figure 13: Mean daily levetiracetam exposure (in women on levetiracetam plus lamotrigine polytherapy)




5
6

Figure 14: Mean daily lamotrigine exposure (in women on levetiracetam plus lamotrigine polytherapy)




7
8

Figure 15: Stillbirth




9
10

Figure 16: Neonatal mortality



1
2

Figure 17: Major congenital malformation



3
4

Figure 18: Admission to Neonatal Intensive Care Unit



5
6

Appendix F GRADE table

Table 7: Clinical evidence profile: therapeutic drug monitoring versus clinical features monitoring

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Therapeutic drug monitoring versus clinical features monitoring	Control	Relative (95% CI)	Absolute		
Quality of life (QOLIE-31 Overall Health) (follow-up from randomisation to 36 weeks gestation; range of scores: 0-10; Better indicated by higher values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision ²	none	115	110	-	MD 0.35 lower (0.72 lower to 0.02 higher)	⊕⊕○○ LOW	CRITICAL
Quality of life (QOLIE-31) (range of scores: 0-100; Better indicated by higher values)												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision ³	none	114	110	-	MD 2.5 lower (5.1 lower to 0.1 higher)	⊕⊕○○ LOW	CRITICAL
Quality of life (EQ-5D) (range of scores: 0-1; Better indicated by higher values)												
1	randomised trials	very serious ⁴	no serious inconsistency	no serious indirectness	no serious imprecision ⁵	none	99	102	-	MD 0 higher (0.05 lower to 0.05 higher)	⊕⊕○○ LOW	CRITICAL
Time to first seizure												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	serious ⁶	none	127	130	HR 0.8 (0.55 to 1.16)	-	⊕○○○ VERY LOW	CRITICAL
								0%		-		
Time to first and subsequent seizures												
1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	very serious ⁷	none	127	130	HR 1.4 (0.73 to 2.68)	-	⊕○○○ VERY LOW	CRITICAL
								0%		-		
Proportion of women who experienced no seizures												

1	randomised trials	very serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision ⁸	none	79/127 (62.2%)	80/130	RR 1.01 (0.83 to 1.22)	6 more per 1000 (from 105 fewer to 135 more)	⊕⊕○○ LOW	CRITICAL
								61.5%				
Maternal mortality												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	serious ¹⁰	none	0/130 (0%)	0/133	RD 0 (-0.01 to 0.01)	-	⊕⊕○○ LOW	CRITICAL
								0%		-		
Maternal admission to HDU/ICU												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ⁷	none	5/127 (3.9%)	3/130	OR 1.8 (0.41 to 7.9)		⊕○○○ VERY LOW	CRITICAL
								2.3%				
Mean daily AED exposure (mg) CBZ monotherapy (Better indicated by lower values)												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ¹¹	none	16	20	-	MD 12.1 lower (226.7 lower to 202.5 higher)	⊕○○○ VERY LOW	CRITICAL
Mean daily AED exposure (mg) LTG monotherapy (Better indicated by lower values)												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	serious ¹²	none	68	70	-	MD 32.3 higher (14.4 lower to 79 higher)	⊕⊕○○ LOW	CRITICAL
Mean daily AED exposure (mg) LEV monotherapy (Better indicated by lower values)												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	serious ¹³	none	31	31	-	MD 166.5 higher (229.8 lower to 562.8 higher)	⊕⊕○○ LOW	CRITICAL
Mean daily AED exposure (mg) LEV + LTG (focus on LEV) (Better indicated by lower values)												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ¹⁴	none	11	14	-	MD 137.3 lower (945.9 lower to 671.3 higher)	⊕○○○ VERY LOW	CRITICAL
Mean daily exposure (mg): LEV + LTG (focus on LTG) (Better indicated by lower values)												

1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	serious ¹⁵	none	11	14	-	MD 97.4 higher (28.7 lower to 223.5 higher)	⊕⊕⊕⊕ LOW	CRITICAL
Stillbirth												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ⁷	none	0/125 (0%)	2/134	OR 0.14 (0.01 to 2.31)	13 fewer per 1000 (from 15 fewer to 19 more)	⊕⊕⊕⊕ VERY LOW	CRITICAL
								1.5%				
Neonatal mortality												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	serious ¹⁰	none	0/126 (0%)	0/134	RD 0 (-0.01 to 0.01)	-	⊕⊕⊕⊕ LOW	CRITICAL
								0%		-		
Major congenital malformation												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ⁷	none	7/125 (5.6%)	10/134	OR 0.66 (0.23 to 1.89)		⊕⊕⊕⊕ VERY LOW	CRITICAL
								7.5%				
Admission to Neonatal Intensive Care Unit												
1	randomised trials	serious ⁹	no serious inconsistency	no serious indirectness	very serious ⁷	none	16/125 (12.8%)	18/134	OR 1.6 (0.29 to 8.83)		⊕⊕⊕⊕ VERY LOW	CRITICAL
								13.4%				

¹ There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome.

² MID for this outcome was calculated as ± 0.8 .

³ The MID for this outcome was ± 6.75 .

⁴ There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias. The RCT component of the study was not blinded and for this outcome participants were outcome assessors. Bias could arise through differential reporting of the outcome. There was a high but similar rate of attrition in both groups.

⁵ The MID for this outcome was ± 0.09 .

⁶ The MID for this outcome was 0.8 and 1.25. The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

⁷ The MID for this outcome was 0.8 and 1.25. The outcome was downgraded by 2 increments as the confidence interval crossed both MIDs.

⁸ MID for this outcome was 0.8 and 1.25.

⁹ There is no clear statement that the allocation sequence was kept concealed from recruiters. This risks selection bias.

¹⁰ Downgraded by 1 increment as the outcome is from a single study with zero events in both arms, and sample size >70 and <350

¹¹ The MID for this outcome was ± 168.2 . The outcome was downgraded by 2 increments as the confidence interval crossed both MIDs.

¹² The MID for this outcome was $-/+74.0$. The outcome was downgraded by 1 increment as the confidence interval crossed one MID.


¹³ The MID for this outcome was $-/+463.25$. The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

¹⁴ The MID for this outcome was $-/+538.75$. The outcome was downgraded by 2 increments as the confidence interval crossed both MIDs.

¹⁵ The MID for this outcome was $-/+45.55$. The outcome was downgraded by 1 increment as the confidence interval crossed one MID.

1
2

Appendix G Economic evidence study selection



* Non-relevant population, intervention, comparison, design or setting; non-English language

**Please note that 1 article related to two questions. For this reason, the numbers listed for each review may not total the number of full text articles assessed for applicability and quality of methodology.

3

Appendix H Economic evidence tables

None

Appendix I Health economic model

No original economic modelling was undertaken for this review question.

Appendix J Excluded studies

J.1 Clinical studies

Table 8: Studies excluded from the clinical review

Study	Exclusion reason
Helde 2005 ²	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Islamiyah 2019 ³	Incorrect study design. Men. Non-pregnant women not planning pregnancy. Incorrect interventions
Jacob 2016 ⁴	Incorrect study design. (narrative review)
Jacob 2019 ⁵	Incorrect study design. (narrative review)
Jannuzzi 2000 ⁶	Non-pregnant women not planning pregnancy. Men
Jarvie 2018 ⁷	Systematic review: study designs inappropriate. (included studies relating to pregnancy were either case reports or observational studies).
Jimenez 2020 ⁸	Not English language. (only abstract is in English language)
Johannessen 2008 ⁹	Incorrect study design. (narrative review)
Kelly 1984 ¹⁰	Incorrect study design. (narrative review)
Kim 2018 ¹¹	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Koch 1983 ¹²	Not English language
Kusznir vitturi 2019 ¹³	TDM was not explored as an exposure
Larkin 1988 ¹⁴	Incorrect study design. (conference abstract)
Leenen 2018 ¹⁵	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Lhatoo 2001 ¹⁶	Men. Non-pregnant women not planning pregnancy. Children. TDM not explored as an exposure
Longo 2009 ¹⁷	Systematic review: study designs inappropriate. Systematic review: literature search not sufficiently rigorous. Systematic review: quality assessment is inadequate. Systematic review: methods are not adequate/unclear
Losada-camacho 2014 ¹⁸	Non-pregnant women not planning pregnancy
Maguire 2016 ¹⁹	Systematic review is not relevant to review question or unclear PICO. Non-pregnant women not planning pregnancy
Mauri llerda 2015 ²⁰	Incorrect study design. (clinical practice guideline)
Mcauley 2002 ²¹	Incorrect study design. (narrative review)
Mehrotra 1990 ²²	Incorrect study design. Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Mikov 2010 ²³	Incorrect study design. (conference abstract)

Study	Exclusion reason
Miskov 2009 ²⁴	Inappropriate comparison. (mean percentage AED dose adjustment (during pregnancy TDM and during postnatal TDM) was compared for women with favourable versus adverse pregnancy outcomes. This was not considered to justify inclusion as there was no comparison of outcomes for TDM versus usual care).
Nilsson 2001 ²⁶	Incorrect study design. Non-pregnant women not planning pregnancy. Men
Nonoda 2014 ²⁷	Population was children aged 2.4 to 18. There was no subgroup analysis of women planning/in/post pregnancy)
Otani 1985 ²⁸	Inappropriate comparison. (The association of altered serum levels of AED with changes in seizure frequency was explored. This was not considered to justify inclusion as there was no comparison of outcomes for TDM versus usual care).
Pack 2006 ²⁹	Incorrect study design. (narrative review)
Patsalos 2008 ³⁰	Incorrect study design. (narrative review)
Patsalos 2018 ³¹	Incorrect study design. (narrative review)
Pennell 2004 ³⁴	Incorrect study design. (narrative review)
Pennell 2006 ³²	Incorrect study design. (narrative review)
Pennell 2008 ³³	Incorrect study design. (narrative review)
Pennell 2008 ³⁷	Inappropriate comparison. Prospective, observational comparison of seizure frequency before pregnancy without TDM, and during the study period with TDM. Seizure frequency stratified by seizure classification (all, or generalised tonic-clonic), but no adjustment for age at onset of epilepsy.
Pennell 2016 ³⁵	Incorrect study design. (narrative review)
Pennell 2018 ³⁶	TDM was not explored as an exposure in this prospective observational study. The exposure variable was epilepsy versus no epilepsy. The primary outcome was proportion achieving pregnancy in 12 months.
Perucca 2003 ³⁸	Incorrect study design. (narrative review)
Pirie 2014 ³⁹	Systematic review: study designs inappropriate
Plumpton 2015 ⁴⁰	Economic analysis. Measurement of drug level was not the intervention. Rather, it was a self-administered questionnaire (implementation intention intervention).
Pulliam 1996 ⁴¹	Retrospective patient record review. Non-pregnant women not planning pregnancy. Men
Rahmathullah 1990 ⁴²	Incorrect interventions. Incorrect population (preschool children)
Rajadhyaksha 1999 ⁴³	Incorrect interventions. Incorrect population (children aged 2 to 14 with intracranial granuloma and seizures)
Raju 1994 ⁴⁴	Incorrect interventions. Non-pregnant women not planning pregnancy. Men. Children aged 12 or over
Ramsay 1994 ⁴⁵	Incorrect population (patients with refractory epilepsy receiving VNS). Incorrect interventions
Rashid 2017 ⁴⁶	Incorrect interventions. Inappropriate comparison
Rath 2009 ⁴⁷	Incorrect study design. (narrative review). Incorrect interventions. Inappropriate comparison
Reardon 2017 ⁴⁸	Non-pregnant women not planning pregnancy. Men. Incorrect interventions. Inappropriate comparison
Reid 2008 ⁴⁹	Incorrect population (children with cerebral palsy). Incorrect interventions
Rektor 2020 ⁵⁰	Incorrect interventions. Non-pregnant women not planning pregnancy. Men

Study	Exclusion reason
Remy 1989 ⁵¹	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Rentmeester 1991 ⁵³	Incorrect population. Incorrect interventions
Rentmeester 1991 ⁵²	Incorrect population. Incorrect interventions
Rezaei 2012 ⁵⁴	Incorrect population. Incorrect interventions
Riaz 2013 ⁵⁵	Incorrect population. Incorrect interventions
Rich 2016 ⁵⁶	Incorrect population. Incorrect interventions
Richardson 1998 ⁵⁷	Incorrect population. Incorrect interventions
Richens 1994 ⁵⁸	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Ridsdale 1997 ⁶¹	Men. Non-pregnant women not planning pregnancy
Ridsdale 2000 ⁵⁹	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Ridsdale 2018 ⁶²	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Ridsdale 2018 ⁶⁰	Non-pregnant women not planning pregnancy. Men. Incorrect interventions
Rieckmann 2012 ⁶³	Incorrect population. Incorrect interventions
Ring 2018 ⁶⁴	Incorrect population. Incorrect interventions
Riveau 2018 ⁶⁵	Incorrect population. Incorrect interventions
Rivera-castano 2012 ⁶⁶	Incorrect population. Incorrect interventions
Robinson 1989 ⁶⁷	Incorrect population. Incorrect interventions
Rogin 2014 ⁶⁸	Incorrect population. Incorrect interventions
Romo 2015 ⁶⁹	Incorrect population. Incorrect interventions
Rosati 2016 ⁷⁰	Incorrect population. Incorrect interventions
Rosenfeld 2015 ⁷¹	Incorrect population. Incorrect interventions
Rosman 1993 ⁷²	Incorrect population. Incorrect interventions
Rosman 2001 ⁷³	Incorrect population. Incorrect interventions
Rossetti 2014 ⁷⁴	Incorrect population. Incorrect interventions
Rts 2011 ⁷⁶	Incorrect population. Incorrect interventions
Rts 2015 ⁷⁵	Incorrect population. Incorrect interventions
Ryvlin 2014 ⁷⁷	Non-pregnant women not planning pregnancy. Men. Incorrect interventions. Inappropriate comparison
Sabers 1995 ⁷⁸	Incorrect population. Incorrect interventions
Sabna 2018 ⁷⁹	Incorrect population. Incorrect interventions
Saccone 2016 ⁸⁰	Systematic review is not relevant to review question or unclear PICO. Incorrect interventions
Sacevich 2018 ⁸¹	Incorrect population. Incorrect interventions
Sachdeo 1992 ⁸²	Incorrect population. Incorrect interventions
Sachdeo 1997 ⁸³	Incorrect population. Incorrect interventions
Sackeim 1993 ⁸⁴	Incorrect population. Incorrect interventions
Sackellares 2004 ⁸⁵	Incorrect population. Incorrect interventions
Sáez-llorens 2002 ⁸⁶	Incorrect population. Incorrect interventions
Sahjipaul 2003 ⁸⁷	Incorrect population. Incorrect interventions
Saida 2017 ⁸⁸	Incorrect population. Incorrect interventions
Salinsky 1995 ⁹⁰	Incorrect population. Incorrect interventions
Salinsky 1996 ⁹¹	Incorrect population. Incorrect interventions

Study	Exclusion reason
Salinsky 2010 ⁸⁹	Incorrect interventions
Salloway 2018 ⁹²	Incorrect population. Incorrect interventions
Saposnik 2016 ⁹³	Incorrect population. Incorrect interventions
Saygin 2002 ⁹⁴	Incorrect population. Incorrect interventions
Schachter 1995 ⁹⁵	Incorrect population. Incorrect interventions
Schechtmann 2010 ⁹⁶	Incorrect population. Incorrect interventions
Schonenberg 2017 ⁹⁷	Incorrect population. Incorrect interventions
Schougaard 2017 ⁹⁸	Incorrect population. Incorrect interventions
Scott 1999 ⁹⁹	Non-pregnant women not planning pregnancy. Incorrect interventions. Inappropriate comparison
Sedman 1990 ¹⁰⁰	Incorrect population. Incorrect interventions
Seo 2007 ¹⁰¹	Incorrect population. Incorrect interventions
Sethi 2002 ¹⁰²	Incorrect population. Incorrect interventions
Seynaeve 2016 ¹⁰³	Incorrect population. Incorrect interventions
Shaw 2006 ¹⁰⁵	Non-pregnant women not planning pregnancy. Incorrect interventions. Inappropriate comparison
Shaw 2010 ¹⁰⁴	Non-pregnant women not planning pregnancy. Men. Incorrect interventions. Inappropriate comparison
Shefner 2009 ¹⁰⁶	Incorrect population. Incorrect interventions
Shi 2020 ¹⁰⁷	Incorrect population. Incorrect interventions
Shim 2006 ¹⁰⁸	Incorrect population. Incorrect interventions
Shorvon 2000 ¹⁰⁹	Incorrect population. Incorrect interventions
Si 2020 ¹¹⁰	Incorrect population. Incorrect interventions
Simpson 2015 ¹¹¹	Incorrect population. Incorrect interventions
Singhi 2002 ¹¹³	Incorrect population. Incorrect interventions
Singhi 2003 ¹¹²	Incorrect population. Incorrect interventions
Singla 2011 ¹¹⁴	Incorrect population. Incorrect interventions
Sivenius 1994 ¹¹⁵	Incorrect population. Incorrect interventions
Smith 1993 ¹¹⁷	Incorrect population. Incorrect interventions
Smith 1994 ¹¹⁶	Incorrect population. Incorrect interventions
Smits 2001 ¹¹⁸	Incorrect population. Incorrect interventions
Sobaniec 2004 ¹¹⁹	Incorrect population. Incorrect interventions
Solanki 2016 ¹²⁰	Incorrect population. Incorrect study design
Solomkin 1985 ¹²¹	Incorrect population. Incorrect interventions
Sotelo 2006 ¹²²	Non-pregnant women not planning pregnancy. Men. Incorrect interventions. Inappropriate comparison
Spivey 1993 ¹²³	Incorrect population. Incorrect interventions
Sprigg 2018 ¹²⁴	Incorrect population. Incorrect interventions
Srinivasakumar 2015 ¹²⁵	Incorrect population. Incorrect interventions
Statler 2019 ¹²⁶	Incorrect population. Incorrect interventions
Stauffer 2014 ¹²⁷	Incorrect population. Incorrect interventions
Stefan 2001 ¹²⁹	Incorrect population. Incorrect interventions
Stefan 2006 ¹²⁸	Incorrect population. Incorrect interventions
Strengell 2009 ¹³⁰	Non-pregnant women not planning pregnancy. Incorrect interventions. Inappropriate comparison
Struys 2017 ¹³¹	Incorrect population. Incorrect interventions
Stupp 2009 ¹³³	Incorrect population. Incorrect interventions

Study	Exclusion reason
Stupp 2014 ¹³²	Incorrect population. Incorrect interventions
Stupp 2017 ¹³⁴	Incorrect population. Incorrect interventions
Sundqvist 1999 ¹³⁵	Incorrect population. Incorrect interventions
Sveinbjornsdottir 1994 ¹³⁶	Incorrect population. Incorrect interventions
Szaflarski 2020 ¹³⁷	Incorrect population. Incorrect interventions
Szer 2004 ¹³⁸	Incorrect population. Incorrect interventions
Tacke 2018 ¹³⁹	Incorrect population
Taghavi ardakani 2010 ¹⁴⁰	Incorrect population. Incorrect interventions
Taghdiri 2013 ¹⁴¹	Incorrect population. Incorrect interventions
Takeuchi 2014 ¹⁴²	Incorrect population. Incorrect interventions
Tang 2014 ¹⁴³	Incorrect population. Incorrect interventions
Tartara 1992 ¹⁴⁴	Incorrect population. Incorrect interventions
Tatum 2001 ¹⁴⁵	Incorrect population. Incorrect study design
Temkin 1990 ¹⁴⁸	Incorrect population. Incorrect interventions
Temkin 1999 ¹⁴⁷	incorrect population. Incorrect interventions
Temkin 2007 ¹⁴⁶	Incorrect population. Incorrect interventions
Tennison 1994 ¹⁴⁹	Incorrect population. Incorrect interventions
Terai 1993 ¹⁵⁰	Incorrect population. Incorrect interventions
Thanh 2002 ¹⁵²	Incorrect population. Incorrect interventions
Thilothammal 1993 ¹⁵⁴	Incorrect population. Incorrect interventions
Thilothammal 1996 ¹⁵³	Incorrect population. Incorrect interventions
Thomas 2001 ¹⁵⁵	Incorrect population. Incorrect interventions
Tilz 2006 ¹⁵⁶	Incorrect population. Incorrect interventions
Titre-johnson 2017 ¹⁵⁷	Incorrect population. Incorrect interventions
Tolbert 2014 ¹⁵⁹	Incorrect population. Incorrect interventions
Tolbert 2015 ¹⁵⁸	Incorrect population. Incorrect interventions
Tolchin 2019 ¹⁶⁰	Incorrect population. Incorrect interventions
Trevathan 2006 ¹⁶¹	Incorrect population. Incorrect interventions
Trinka 2018 ¹⁶²	Incorrect population. Incorrect interventions
Trudeau 1996 ¹⁶³	Incorrect population. Incorrect interventions
Tsounis 2011 ¹⁶⁴	Incorrect population. Incorrect interventions
Tungmanowutthikul 2019 ¹⁶⁵	Incorrect population. Incorrect interventions
Turan guruhopur 2018 ¹⁶⁶	Incorrect population. Incorrect interventions
Uijl 2009 ¹⁶⁷	Incorrect population. Incorrect interventions
Vaghadia 1999 ¹⁶⁸	Incorrect population. Incorrect interventions
Vahedi 2007 ¹⁶⁹	Incorrect population. Incorrect interventions
Van der meyden 1994 ¹⁷⁰	Incorrect population. Incorrect interventions
Van paesschen 2013 ¹⁷¹	Incorrect population. Incorrect interventions
Van stuijvenberg 1998 ¹⁷²	Incorrect population. Incorrect interventions
Vanlandingham 2020 ¹⁷³	Incorrect population. Incorrect interventions
Vining 1987 ¹⁷⁴	Incorrect population. Incorrect interventions
Viscusi 2014 ¹⁷⁵	Incorrect population. Incorrect interventions
Wakelee 2017 ¹⁷⁶	Incorrect population. Incorrect interventions
Wang 2008 ¹⁷⁷	Incorrect population. Incorrect interventions
Wanigasinghe 2017 ¹⁷⁸	Incorrect population. Incorrect interventions

Study	Exclusion reason
Webster 2014 ¹⁷⁹	Incorrect population. Incorrect interventions
Weiden 2020 ¹⁸⁰	Incorrect population. Incorrect interventions
Weinbroum 1996 ¹⁸¹	Incorrect population. Incorrect interventions
Welch 2015 ¹⁸²	Incorrect population. Incorrect interventions
Wheless 2019 ¹⁸³	Incorrect population. Incorrect interventions
Wietholtz 1989 ¹⁸⁴	Incorrect population. Incorrect interventions
Wijnen 2017 ¹⁸⁵	Incorrect population. Incorrect interventions
Wilky 2019 ¹⁸⁶	Incorrect population. Incorrect interventions
Wu 2009 ¹⁸⁷	Incorrect population. Incorrect interventions
Xu 2004 ¹⁸⁹	Incorrect population. Incorrect interventions
Xu 2007 ¹⁸⁸	Incorrect population. Incorrect interventions
Yadegary 2015 ¹⁹⁰	Incorrect population. Incorrect interventions
Yamamoto 2016 ¹⁹¹	Incorrect study design. Inappropriate comparison
Yamamoto 2020 ¹⁹²	Incorrect population. Incorrect interventions
Yen 2000 ¹⁹³	Incorrect population. Incorrect interventions
Young 2004 ¹⁹⁵	Incorrect population. Incorrect interventions
Young 2006 ¹⁹⁴	Incorrect population. Incorrect interventions
Younus 2018 ¹⁹⁶	Incorrect population. Incorrect interventions
Zamponi 1999 ¹⁹⁷	Incorrect population. Incorrect interventions
Zhang 2017 ¹⁹⁸	Incorrect population. Incorrect interventions
Zhao 2019 ¹⁹⁹	Incorrect population. Incorrect interventions
Zhong 2018 ²⁰⁰	Incorrect population. Incorrect interventions
Zhou 2017 ²⁰¹	Incorrect population. Incorrect interventions
Zou 2010 ²⁰²	Incorrect population. Incorrect interventions

1

2 J.2 Health Economic studies

3 Published health economic studies that met the inclusion criteria (relevant population,
4 comparators, economic study design, published 2004 or later and not from non-OECD
5 country or USA) but that were excluded following appraisal of applicability and
6 methodological quality are listed below. See the health economic protocol for more details.

7 **Table 9: Studies excluded from the health economic review**

Reference	Reason for exclusion
None.	

8

Appendix K Research recommendations – full details

What is the clinical and cost effectiveness of decisions about therapeutic drug monitoring (TDM) in girls, young women, and women with epilepsy? Particular focus should be on anti-seizure medications where concentrations are known to potentially change during pregnancy.

Research recommendation

What is the clinical and cost effectiveness of decisions about therapeutic drug monitoring (TDM) in girls, young women, and women with epilepsy?

Why this is important

There is evidence of increased risks for women with epilepsy in pregnancy, including ten-fold increased risk of maternal mortality, and risks of worsening seizure control.

Maternal tonic clonic seizures especially if occurring in sleep are associated risks of sudden unexpected death in epilepsy (SUDEP), and status epilepticus.

In addition to major risks to the mother, uncontrolled epilepsy with generalised tonic clonic convulsions is associated with risks of harm to the fetus including miscarriage, fetal hypoxia and acidosis, and fetal loss. The effect of seizures can impact daily living, resulting in loss of driving licence, negative impact on employment and relationships and reduced quality of life (QoL), all of which are heightened in pregnancy.

The potential for ASM (antiseizure medication) serum concentrations changing in pregnancy has become a focus of clinical management in pregnancy, with variable implementation in the UK for epilepsy monitoring before, during and after pregnancy. The focus on maintaining a stable ASM concentration during and after pregnancy is difficult owing to the alteration of ASM pharmacokinetics including increased volume of distribution, elevated renal clearance, and induction of hepatic metabolism. There is evidence lamotrigine, levetiracetam, oxcarbazepine and phenytoin serum concentrations potentially change during pregnancy.

There is uncertainty of how best to manage the changes in ASM concentration, to influence improvement in pregnancy and post-pregnancy seizure control, while mitigating ASM toxicity for mother and baby.

In the face of uncertainty of how best to manage the risks of changes ASM serum concentrations pregnancy, it is important to investigate the effectiveness of therapeutic drug monitoring (TDM) in girls, young women, and women with epilepsy, especially focusing on anti-seizure medications where concentrations are known to potentially change during pregnancy.

Rationale for research recommendation

Importance to 'patients' or the population	Little is known of the best approach to managing ASM serum concentrations before, during and after pregnancy, and the potential benefits and harms of different management strategies. There are significant risks associated with maternal seizures in pregnancy and risks of SUDEP and maternal death has been linked to finding sub-therapeutic drug levels. This has raised concern of the potential to reduce avoidable maternal death, and there is significant public and political concern about this.
Relevance to NICE guidance	Therapeutic drug monitoring (TDM) before, during and after pregnancy has been considered in this guideline due to the uncertainty of effective management and variable implementation

	in practice. There is need for focused attention on the effective management strategies for TDM, particularly for lamotrigine, levetiracetam, oxcarbazepine and phenytoin as evidence of potential serum levels changing in pregnancy exists.
Relevance to the NHS	<p>The outcome would affect the management of ASM in pregnancy, particular the routine uses of TDM before, during and after pregnancy provided by the NHS. This may also predict future healthcare needs for women with epilepsy before, during and after pregnancy.</p> <p>The outcome may have potential cost and resource implication as this is not routine practice in the NHS. The work offers clear benefit with the potential outcome of influencing ASM prescribing in pregnancy; the opportunity to reduce fetal ASM exposure (for example by preventing erroneous increases in ASMs during pregnancy) and ensuring that risks for post-partum risks of ASM toxicity are minimised</p>
National priorities	High
Current evidence base	<p>Evidence was provided by a single randomised controlled trial of TDM versus clinical features monitoring (CFM) among women under 24 weeks gestation in whom ASM concentrations had fallen by 25% or more.</p> <p>It was agreed that this trial was inconclusive, neither providing straightforward evidence in favour of TDM in pregnancy, nor providing clear evidence against it. This research recommendation was therefore made for further study to address the clinical and cost effectiveness of decisions about TDM in girls, young women, and women with epilepsy.</p>
Equality considerations	The variable implementation of TDM in current practice has uncertain impact on equitable care provision. This research recommendation will focus on women with epilepsy of all ethnicities who have potential for pregnancy, without age restriction including girls under the age of 16 years, and including women with intellectual disabilities, and those within following vulnerable groups.

1

Modified PICO table

Population	Girls, young women, and women with epilepsy who are of childbearing potential
Intervention	Anti-seizure medication therapeutic drug monitoring
Comparator	Different TDM strategies; clinical features monitoring; different ASM
Outcome	Mortality of mother or baby at study follow-up, seizure freedom during pregnancy and at six months post-partum, reduction in seizure frequency (50% or more), time to first seizure in pregnancy and up to up to six weeks post-partum, time to subsequent seizures (within an observation period of up to one year), ASM exposure (mean daily), and quality of life (using any validated measures) at study follow-up. Adverse events: ASM toxicity, pregnancy complications in the mother or baby (maternal admission to a high dependency or intensive care unit or admission of the baby to a neonatal intensive care unit), seizures during labour, attendance at an emergency department, congenital anomalies, and neurodevelopmental outcomes.

Study design	RCT; Prospective study design
Timeframe	From pre-pregnancy, pregnancy and up to 12m post-partum. Long term.
Additional information	None

1
2

Appendix L Additional information

Algahtani, H., et al. (2019). "Antiepileptic Drugs Usage in Pregnant Women with Epilepsy in Saudi Arabia." Journal of Epilepsy Research **9**(2): 134-138.

Background and Purpose: Epilepsy is one of the most common neurological disorders requiring continuous treatment during pregnancy. In Saudi Arabia, there is only one publication that studied the outcome of pregnancies in women with epilepsy, published in 1999. The aim of the study is to determine the major congenital malformations in infants resulting from exposure to antiepileptic drugs in pregnant women with epilepsy.

Methods: This is a retrospective observational study that was conducted at King Abdulaziz Medical City, Jeddah, Saudi Arabia, involving pregnant women with epilepsy using antiepileptic drugs during pregnancy. We also studied babies born to those mothers. The study period was 5 years from 2014 to 2018.

Results: Six hundred babies were included in the study, born to 154 mothers with epilepsy using antiepileptic drugs during pregnancy. In addition, there were 111 losses of fetuses before 20 weeks of gestation. The only malformation detected was a ventricular septal defect in one child, whose mother was using polytherapy (valproic acid and levetiracetam). Three babies were born with epilepsy, and four babies had other associated disorders (Down syndrome, osteoporosis, esotropia, and hearing impairment).

Conclusions: The results of this small study are an urgent call for the establishment of congenital malformations registry in Saudi Arabia. In addition, specialized epilepsy clinics utilizing multidisciplinary care are highly recommended. A specific group of interest for such clinics are married women, who have epilepsy and are using antiepileptic drugs since planning of pregnancy is not part of the culture in Saudi Arabia. Copyright © 2019 Korean Epilepsy Society.